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ABSTRACT 
Raymond George Fox: Uncovering the Protective Role of PolgD257A, a Mitochondrial DNA 
Mutator, on Diabetes and Obesity 
 (Under the direction of Nobuyo Maeda, PhD) 
Mitochondria are highly conserved organelles, found in most cells throughout the 
body, and perform many essential biological processes. Mitochondria are responsible for 
the production of energy in the form of ATP that is required to maintain normal function in 
eukaryotic cells. While this is beneficial to the cell, mitochondria have the unique role in 
initiating cell death. It is not surprising that mitochondrial dysfunction is the hallmark of 
many metabolic disorders such as maternally inherited diabetes and deafness. Some 
evidence suggests that mitochondrial dysfunction via mitochondrial DNA damage in the 
form of DNA deletions and mutations can contribute to complications associated with 
diabetes, yet a causal role of mitochondrial DNA mutations in diabetic complications has 
not been answered. The PolgD257A mutant mouse disrupts the proofreading domain of 
DNA polymerase gamma resulting in the random accumulation of mitochondrial DNA 
mutations. The research presented in this dissertation aims to utilize the PolgD257A mutant 
mouse as a genetic tool to further investigate the role that accumulating mitochondrial 
DNA mutations have in diabetes, obesity, and diabetic complications.  
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I demonstrate that accumulating mitochondrial DNA mutations in “Akita” diabetic 
mice improves the diabetic phenotype of the male mice. Within this study, I determined 
that mitochondrial dysfunction in the testis reduces appetite thereby improving diabetes, 
underlining the importance of hyperphagia in the diabetic Akita mouse. Over the course of 
this study, I uncovered a phenotype of the small intestine that was not described previously. 
In a separate study, I characterized the small intestine phenotype demonstrating that the 
PolgD257A mutation disrupts the cell cycle of the rapidly dividing cells in the small 
intestine leading to an increase in cell death. While the small intestine phenotype does not 
seem to cause an observable phenotype in the PolgD257A mice, the final study 
investigated the functional aspect of the small intestine by challenging the mice with a high 
fat, high carbohydrate diet. The diet challenged mice were protected against obesity 
suggesting a role for mitochondria in normal lipid absorption. Together, these studies have 
elucidated the unexpected role of mitochondrial DNA mutations in reversing diabetes and 
preventing obesity. 
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C h a p t e r  1  
INTRODUCTION 
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1.1 Mitochondria 
The origin of mitochondria in eukaryotic cells has been a controversial topic since the 
early 20th century. Multiple theories have been proposed. The discovery of small circular 
DNA of mitochondria in animal tissues in the 1960’s by Rabinowitz et al provided some 
evidence to the theory that mitochondria originated from a bacterial source (1). However, it 
was not until the 1980’s that Dr. Lynn Margulis’ theory of endosymbiosis was accepted as 
the most plausible origin of mitochondria (2). The endosymbiosis theory states that 
mitochondria originate from an ancient bacterial species being engulfed, but not lysed, by an 
early eukaryotic cell forming a mutually beneficial symbiotic relationship (3). During 
evolution, eukaryotic cells began to rely on mitochondria for efficient production of ATP (4). 
The human body is a prime example of utilization of this symbiotic relationship. 
There are many cells in the human body that require high energy production, including 
neurons, hair cells of the inner ears, heart and skeletal myocytes, pancreatic beta cells, as 
well as gut and kidney epithelial cells; and all of these cell types are highly packed with 
mitochondria (5-9). Mitochondria provide the highly specialized functions of energy 
production, cell death/apoptosis signaling, and regulation of cell cycle (10). The highly 
specialized efficient production of ATP has earned mitochondria the nickname “powerhouse 
of the cell.” The number of mitochondria per cell in the human body varies from tissue to 
tissue and is dependent on the level of metabolic activity of the cell. Wiesner et al estimated 
by PCR that there are on average approximately 1-3 copies of mitochondrial DNA (mtDNA) 
per rat mitochondria, and this varies in number depending on the tissue (11). 
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1.2 Mitochondrial DNA Mutations and Aging  
Elucidating the mechanism of aging has become an important issue for the medical 
sciences. As people live longer, the cost to combat aging-related disease has become a 
burden for society. It has become apparent that mitochondria play an influential role in the 
aging process (12-22). This is not surprising since mitochondria are essential for maintaining 
the metabolic activity of the cells throughout the body, and that any metabolic imbalance 
would alter cellular function within a particular tissue. The mitochondrial theory of aging is 
based on the idea that reactive oxygen species (ROS) damage mitochondrial DNA (23-25).  
With age, an accumulation of DNA damage leads to irreversible dysfunction of the 
mitochondrion and an eventual aging phenotype.  
Epidemiological studies comparing young and old individuals have described a 
significant increase in mitochondrial DNA mutations in older individuals (26). Comparison 
of DNA sequence of mitochondria from young and old mice showed that aged mice have 
significantly higher levels of mtDNA mutations than younger mice (27). Despite the 
evidence for accumulating mitochondrial DNA mutations in aging, however, debate has 
persisted related to the causal role of mitochondrial mutations in the aging process: does 
aging cause increased mtDNA mutations or are accumulation of mtDNA mutations sufficient 
for aging? A recent mouse model of aging suggests that mitochondrial DNA mutations are 
the driving force behind the aging process (18, 21). 
1.3 Mitochondria in Disease 
Several progressive age-related diseases have been directly linked to point mutations 
found throughout the mitochondrial genome. Mitochondrial disorders affect many organ 
systems through out the body including the brain, eyes, pancreas, skeletal muscles, 
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gastrointestinal system, and heart. Surprisingly, a single base change in the mitochondrial 
genome is sufficient to cause a mitochondrial disease. Tables 1.1 and 1.2 summarize the 
point mutations found to date in mtDNA and the disorder linked to the change in either a 
mitochondrial gene or a mitochondrial tRNA. The vast majority of point mutations found 
involve mutations in tRNAs.  
Table 1.1: Disorders with mitochondrial DNA mutations in mitochondrial genes 
Mutation Gene Clinical phenotype References 
A1555G 12s rRNA deafness, aminoglycoside ototoxicity Prezant 1993 (28) 
T8993C ATPase 6 Leigh Disease de Vries 1993 (29) 
T8993G ATPase 6 Leigh Disease Tatuch 1992 (30) 
T9185C ATPase 6 Leigh Disease Moslemi 2005 (31) 
T9191C ATPase 6 Leigh Disease Moslemi 2005 (31) 
T8993G ATPase 6 Neuropathy, ataxia, retinitis pigmentosa Holt 1990 (32) 
T9957C  COXIII MELAS Manfredi 1995 (33) 
G13513A ND5 MELAS Santorelli 1997 (34) 
G15059A CYTB fatigue, muscle weakness, exercise intol. Andreu 1999 (35) 
G11832A ND4 Exercise intolerance Andreu 1999 (36) 
G3460A ND1 LHON Huoponen 1991 (37) 
T4160C ND1 LHON Howell 1991  
A4136G ND1 LHON Howell 1991 (38) 
A11696G ND4 LHON de Vries 1996 (39) 
G11778A ND4 LHON Wallace 1988 (40) 
G14459A ND6 LHON Jun 1994 (41) 
T14484C ND6 LHON Johns 1992 (42) 
T10191C ND3 epilepsy, stroke-like episodes, optic atrophy  Taylor 2001 (43) 
T10158C ND3 infantile encephalopathy McFarland 2004 (44) 
 (LHON – Lieber’s Hereditary Optic Neuropathy, MELAS - Mitochondrial Encephalomyopathy, Lactic Acidosis, 
and Stroke-like episodes)
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Table 1.2: Disorders with mitochondrial DNA mutations in tRNAs 
Mutation tRNA Clinical phenotype References 
A4336G tRNA-Gln Alzheimers/Parkinsons Egensperger 1997 (45) 
A4300G tRNA-Ile Cardiomyopathy Casali 1995 (46) 
C3303T tRNA-Leu Cardiomyopathy Silvestri 1994 (47) 
A3260G tRNA-Leu Cardiomyopathy, myopathy Zeviani 1991 (48) 
A4269G tRNA-Ile Fatal cardiomyopathy Taniike 1992 (49) 
A3243G tRNA-Leu diabetes and deafness van den Ouweland 1992 (50) 
C4320T tRNA-Ile Encephalomyopathy Santorelli 1995 (51) 
T14709C tRNA-Glu Encephalomyopathy Hanna 1995 (52) 
G12315A tRNA-Leu Encephalomyopathy Fu 1996 (53) 
G15915A tRNA-Thr Encephalomyopathy Nishino 1996 (54) 
G8313A tRNA-Lys encephaloneuropathy, GI Verma 1997 (55) 
A5814G tRNA-Cys Encephalopathy Manfredi 1996 (56) 
G5549A tRNA-Trp Encephalopathy Nelson 1995 (57) 
G8363A tRNA-Lys Encephalopathy, hearing loss, cardiomyopathy Santorelli 1996 (58) 
G8363A tRNA-Lys Neuropathy Pineda 2004 (59) 
A15923/4G tRNA-Thr Fatal, infantile Respiratory defect Yoon 1991 (60) 
T7511C tRNA-Ser hearing loss  Sue 1999 (61) 
T7445C tRNA-Ser hearing loss Reid 1994 (62) 
T9997C tRNA-Gly hypertrophic Cardiomyopathy Merante 1994 (63) 
A4295G tRNA-Ile hypertrophic Cardiomyopathy Merante 1996 (64) 
T7512C tRNA-Ser MERRF/MELAS Nakamura 1995 (65) 
A8344G tRNA-Lys Myoclonic epilepsy, myopathy Shoffner 1990 (66) 
T8356C tRNA-Lys Myoclonic epilepsy, myopathy Silvestri 1992 (67) 
A12320G tRNA-Leu Myopathy Weber 1997 (68) 
A3288G tRNA-Leu Myopathy Hadjigeorgiou 1999 (69) 
A3302G tRNA-Leu Myopathy Bindoff 1993 (70) 
T3250C tRNA-Leu Myopathy Goto 1992 (71) 
G15990A tRNA-Pro Myopathy Moraes 1993 (72) 
T14709C tRNA-Glu myopathy, weakness, diabetes Hao 1995 (73) 
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A3243G tRNA-Leu MELAS Goto 1990 (74) 
A3252G tRNA-Leu MELAS Morten 1993 (75) 
T3271C tRNA-Leu MELAS Goto 1991 (76) 
T3291C tRNA-Leu MELAS Goto 1994 (77) 
T5537l tRNA-Trp MELAS Santorelli 1997 (78) 
G1642A tRNA-Val MELAS Taylor 1996 (79) 
G5703A tRNA-Asn PEO Moraes 1993 (80) 
T4285C tRNA-Ile PEO Silvestri 1996 (81) 
C3256T tRNA-Leu PEO Moraes 1993 (80) 
A10044G tRNA-Gly Unexpected Death Santorelli 1996 (82) 
(PEO – Progressive External Ophthalmoplegia, MELAS - Mitochondrial Encephalomyopathy,  
Lactic Acidosis, and Stroke-like episodes, MERRF - Myoclonic Epilepsy with Ragged Red Fibers) 
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Diabetes and Obesity 
Diabetes mellitus is becoming increasingly common worldwide.  Type 1 diabetes 
accounts for 5 to 10 percent of all cases of diabetes in the US (83). Type 1 diabetes is 
characterized by the inability of the pancreas to produce sufficient insulin to effectively lower 
blood glucose levels. In humans, type 1 diabetes is classified as a chronic autoimmune disorder 
that destroys the beta cell of the pancreatic islets (84, 85). The exact trigger of the autoimmune 
response still remains a mystery (85). However, it has been reported that auto reactive T-cell 
destruction of beta cells is a contributing event that leads to autoimmune diabetes in humans 
(86). In support of this mechanism, the activated T-cells lead to beta cell apoptosis followed by 
progression to diabetes in non-obese diabetic (NOD) mice that have a mutation in (87-90).  
Obesity and type 2 diabetes is becoming increasingly common worldwide.  In the US, 
type 2 diabetes accounts for 90 to 95 % of all cases of diabetes with a growing portion of the 
diabetic cases occurring in young individuals. Type 2 diabetes is characterized by the insulin 
resistance of peripheral tissues leading to prolonged elevation of insulin levels. There is a large 
body of data demonstrating links between mitochondrial dysfunction, insulin resistance, and 
type 2 diabetes (91). 
Mitochondrial Dysfunction and Diabetes 
A subset of diabetic patients is classified as having maternally inherited diabetes and 
deafness (MIDD). MIDD has been traced to a point mutation in the mitochondrial DNA 
producing A3243G in tRNA-Leu (50, 92). Although, only one instance of a maternally 
inherited point mutation that leads to diabetes and deafness has been discovered so far, there is 
a potential for greater number of point mutations that lead to diabetes and obesity since new 
mutations are being added to a growing database of mitochondrial diseases. Whether defects 
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caused by mtDNA mutations are sufficient to induce diabetes remains unknown. However, 
since mitochondria are key to energy metabolism, one could speculate that mtDNA mutations 
would lead to diabetes. Mitochondrial dysfunction caused by mutations in mitochondrial DNA 
can directly influence the development of type I diabetes through effects on the production of 
insulin (92). It remains unclear whether the mitochondrial problems act causally with respect to 
diabetes or are consequences of the condition. A recent study has shown that adipocyte 
dysfunction was caused by a reduction in the number of mitochondria in adipocytes leading to 
the development of type 2 diabetes (93). However, this study did not explore the cause of the 
reduction in mitochondria: is it related to mitochondrial dysfunction? Further links involving 
mitochondrial related problems with adipocytes leading to the development of obesity and type 
2 diabetes have been described with emphasis on adipocyte dysfunction, metabolic overload, 
and inflammatory damage to adipocytes (94). It has been suggested that mitochondrial 
dysfunction is a contributing factor in the insulin resistance of peripheral tissues, the secretion 
of insulin from the beta cells, energy expenditure, and removal of ROS all of which contribute 
to type 2 diabetes (95-98). Since, insulin secretion from the beta cells requires ATP, it is not 
surprising that mitochondrial dysfunction would lead to impaired release of insulin in response 
to glucose. Thus, the causal role of mitochondrial DNA mutations in diabetes and obesity 
remains an important question.  
Diabetic Complications 
Prolonged diabetes can damage the cardiovascular system, kidney, retina, peripheral 
and central nervous system, and muscles leading to serious complications that increase the risk 
of morbidity and mortality. This dissertation focuses on one complication, diabetic 
nephropathy. Diabetic nephropathy is the major cause of end stage renal disease in the United 
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States, but not all diabetic patients develop nephropathy (83). This suggests underlying genetic 
factors may contribute towards nephropathy in select individuals. Mouse models are ideal in 
studying the pathophysiology of diseases such as nephropathy. However, mouse models have 
their limitations in the study of human disease because they often do not recapitulate the 
disease. For instance, C57BL/6 mice are relatively resistant to nephropathy while other models 
do not exhibit all the characteristics of human renal disease (99, 100).  
Previous work in our lab suggests a link between mitochondrial DNA mutations and 
diabetic nephropathy. Interestingly, removal of the bradykinin B2 receptor in diabetic “Akita” 
mice enhanced nephropathy (101). In addition, a premature aging phenotype was described in 
mice with the diabetic Akita mutation and the removal of B2-receptor (102). These mice also 
had increased mtDNA mutations, mtDNA deletions, and many symptoms of aging (hair loss, 
kyphosis, and osteoporosis). However, neither study addressed whether mitochondrial DNA 
mutations contribute directly to the diabetic nephropathy or if the mtDNA mutations are simply 
a consequence of the disease. This prompted an evaluation of the contribution of mtDNA 
mutations in the development of diabetic nephropathy. 
1.4 Mitochondrial Replication 
Mitochondria contain their own circular DNA that is approximately 16.3 kB in length 
in mice (103). During cell division, mother cells must replicate mitochondria in order to 
provide daughter cells with enough mitochondria to grow, function, and survive. The 
duplication of mitochondria requires the synthesis of mtDNA followed by mitochondrial 
division via fission. Mitochondrial fission is the process by which mitochondria divide into two 
identical organelles (104). Mitochondrial fission is regulated through an interaction between 
hFisp1, a mitochondrial protein, and DLP1, Dynamin-like protein (105-107). Mitochondria 
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also undergo fusion in order to maintain the numbers of functional mitochondria in the cell. 
Mitochondrial fusion machinery consists of two GTPases, Mtn1 and OPA1, which when 
combined cause a linkage between mitochondria and results in the fusion event (108). The 
balance of mitochondrial fusion and fission is essential in the maintenance of functional 
mitochondria and normal cellular function. Any imbalance in fusion and fission results in loss 
of function, fragmentation of mitochondria, and apoptosis (109, 110). Prior to mitochondrial 
fission, mtDNA must be replicated in order to provide the newly generated mitochondrion the 
genetic information required to produce the enzymes associated with the electron transport 
chain. Mitochondria DNA replication occurs by asymmetric strand displacement replication 
(111-114). Briefly, synthesis of mtDNA is initiated at the origin of heavy strand (OH) by  
mtDNA polymerase gamma (Polg). The OH strand is replicated displacing the light strand (OL) 
allowing single stranded binding protein (SSB) to bind to the OL strand until the replication of 
OH has proceeded past OL at which point Polg begins replicating the light strand. 
1.5 Mitochondrial DNA Polymerase gamma 
Mitochondrial DNA polymerase gamma (Polg), a nuclear encoded gene, is solely 
responsible for replication and proofreading of mitochondrial DNA. Mouse Polg and human 
POLG genes, located on chromosome 7 and 15, respectively, consist of 23 exons, and are well 
conserved (115). The POLG protein has three exonuclease domains that contribute to the 
fidelity of the polymerase (116). Human polymerase γ contains a catalytic core (pol γ-α), 
which consists of the polymerase and exonuclease domains, and an accessory subunit (pol γ-β), 
which is a dimer and stimulates DNA binding and holoenzyme processing (Fig. 1.1) (117). 
Figure 1.2 illustrates a schematic of the gene and protein structure of Human POLG. Figure 1.2 
also illustrates the known polymorphisms found in POLG and their association with disease 
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(118). In humans, there have been approximately 150 mutations consisting of both mtSNPs and 
point mutations (associated with disease) described in POLG (118). Point mutations in POLG 
cause an increase in mtDNA deletions (119). Recently a new body of work has underlined the 
importance of point mutations in POLG that directly lead to various neurological diseases in 
human patients. For example, a point mutation G451E in the linker region of POLG directly 
causes progressive external ophthalmoplegia by disruption of mitochondria maintenance (120, 
121). Two point mutations, A467T and R627W, (found in the linker region) in POLG lead to 
Sensory Ataxic Neuropathy, Dysarthria and Ophthalmoparesis (SANDO) (121). Two recent 
reports described the W748S mutation, also in the linker region of POLG, as a cause of 
autosomal recessive neurodegenerative disorders (122, 123). Furthermore, mutations Y955C 
and R953C, located in the polymerase domain, and mutation N468D located in the linker 
region of POLG, have been found to co-segregate with Parkinsonism (124). Polg in mice is 
essential for life since removal of the gene leads to embryonic developmental arrest at E7.5-
E8.5 (125). In Saccharomyces cerevisiae, ablating the exonuclease domain activity leads to an 
approximately 500 to 1500-fold increase in mitochondrial DNA mutations (126, 127). In 
summary, POLG is essential for life, provides both replication and proofreading of mtDNA, 
and point mutations in the gene have a wide-ranging impact on the human population in 
neurological and muscle disorders. 
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Figure 1.1: Structural model of human pol 
γ   
A) Accessory Pol γ-β subunits (green and 
yellow) interacting with the catalytic Pol γ-α 
core (blue and orange ribbons), and binding 
to dsDNA (magenta). F – finger, P – palm, 
and T – thumb domains of polymerase.  
(B) Alternate view of the Pol γ complex with 
clear view of E - exonuclease domain of 
polymerase. 
Note: Thioredoxin (gray) from T7 DNA 
polymerase is not found in Pol γ. 
“Reprinted from Journal of Molecular 
Biology, 358, Fan L, et al., A Novel 
Processive Mechanism for DNA Synthesis 
Revealed by Structure, Modeling and 
Mutagenesis of the Accessory Subunit of 
Human Mitochondrial DNA Polymerase, 
1229-1243, Copyright (2006), with 
permission from Elsevier.” 
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Figure 1.2: Illustration of Human polymerase γ  (POLG) and point mutations associated 
with disease. POLG gene (top) consists of 23 exons. The POLG protein (bottom) structure is 
highlighted by a mitochondrial targeting sequence, exonuclease domain, linker region, and 
polymerase domain. Boxes represent amino acid changes causes by point mutations within the 
mitochondrial genome and the disease associated with the mutation. “With kind permission 
from Springer Science+Business Media: Cellular and Molecular Life Sciences, Mitochondrial 
DNA replication and disease: insights from DNA polymerase γ mutations, (2011) 68:219-233, 
Stumpf, JD and Copeland, WC, Figure 3, © Springer Basel AG (outside the USA) 2010.” 
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1.6 Mitochondrial DNA Mutator Mice (Polg-D257A) 
The creation of mitochondrial DNA mutator mice, which displays many of the 
phenotypes of aging as well as a reduced lifespan, have helped to shed light on the causal 
role of mitochondrial mutations in aging. A mutation from aspartic acid to alanine at amino 
acid position D230A in POLG has been reported to cause an ablation of the proofreading 
domain of the polymerase without affecting the replication efficiency of the polymerase 
resulting in a premature aging phenotype (126, 127). Aspartate residues are important for the 
catalytic function of exonuclease activity of POLG and are evolutionarily conserved (127). 
Two independent groups introduced the POLG-D257A mutation in mice. Homozygous 
mutants have an acceleration of mitochondrial DNA mutations over the lifespan of the mouse 
(18, 21). As seen in Figure 1.3, the mutation decreases lifespan to 13 months in Polg mice 
homozygous for D257A mutation compared to 30 months in wild type mice. Physical signs 
of premature aging include hair loss, kyphosis, and decreased bone density. The major tissues 
affected by this mutation are the highly proliferating tissues of the bone marrow, skin, testis, 
and small intestine (18, 21). Chen et al recently reported that the PolgD257A/D257A mice die 
prematurely due to a severe fatal anemia caused by mitochondrial dysfunction (128). The 
amount of mtDNA mutations accumulated in 13-month old PolgD257A/D257A mice has been 
estimated as high as 1x10-3 mutations/bp in most tissues compared to <5x10-4 mutations/bp 
in wild type mice (18, 21, 129, 130). Since Polg is a processing enzyme mitochondrial DNA 
mutations are increased in the heterozygous Polg-D257A mice compared to wild type mice 
(18, 21). However, heterozygotes have a natural lifespan and show no aging-associated 
phenotype. The authors suggested the premature aging phenotypes is not because of 
nucleotide substitutions in mitochondrial DNA but because of deletions in mtDNA which is 
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increased by 90 fold in homozygotes compared to heterozygotes (18, 21).  It is noted that the 
PolgD257A/D257A mice display many of the age-related phenotypes seen in human aging (129). 
Nevertheless, the PolgD257A/D257A mice provide a genetic means to artificially induce global 
increases in mitochondrial DNA mutations, and this tool will provide us with a means to 
study the effects of mitochondrial DNA mutations on pathophysiology of age-related 
diseases such as diabetes and obesity. 
 
Figure 1.3: Premature aging phenotype induced by the Polg-D257A mutation.  (A) Wild type and (B) the 
accelerated aging phenotype of PolgD257A/D257A mice are shown at ~ 13 months of age, with Polg mice displaying 
hair loss and kyphosis that is commonly associated with aging in humans. (C) Reduced survival of Polg 
homozygous (D257A/D257A) compared to Polg heterozygous (D257A/+) and wild type (+/+) mice. From 
Kujoth GC, et al. (2005) Mitochondrial DNA mutations, oxidative stress, and apoptosis in mammalian aging. 
Science (New York, N.Y.) 309(5733):481-484. Reprinted with permission from AAAS. 
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1.7 Mouse Models Used for these Studies 
PolgD257A/D257A Mice, a Mitochondrial DNA Mutator Mouse 
For induction of mitochondrial DNA mutations, I employed the use of a mutation in 
Polymerase gamma (D257A) that ablates the proofreading activity without affecting the 
replication activity of the enzyme. As described earlier in section 1.6, the PolgD257A/D257A mouse 
develops a premature aging phenotype with hair loss, graying of the hair, and kyphosis (18, 
21). Furthermore, the Polg mutant mice have increased cell apoptosis and no changes to ROS 
(18, 21). The median lifespan of this model is 13 months of age, and the extent of the lifespan 
is determined by the severity of a fatal anemia that these mice are prone to developing (128). 
There is a general increase in mitochondrial DNA mutations in all tissues especially tissues 
which are actively proliferating (small intestine, skin, testis, and bone marrow) or metabolically 
active (liver). While there have been no reports of diabetes or obesity in the Polg-D257A 
mouse model, therefore it is suitable to test whether increased mtDNA mutations would 
accelerate diabetes related complications. 
Akita (Ins2C96Y/+) Mice, a Mouse Model of Type 1 Diabetes 
While there are several models available for the study of type 1 diabetes (131), I chose 
a well-studied genetic model of type 1 diabetes caused by a  depletion of insulin due to a 
spontaneous mutation in the Insulin 2 gene of the mouse (132, 133). This model, termed Akita, 
is a well-established and frequently used model for type 1 diabetes. The Akita mouse has an 
amino acid change at position 96 from cytosine to tyrosine that disrupts the disulfide bond that 
keeps Insulin 2 properly folded. Accumulation of the mis-folded pro-insulin in the pancreatic 
beta cell induces endoplasmic reticulum stress, and eventually causes beta cell apoptosis (134). 
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Homozygous males with the Akita mutation die at about 8 weeks of age due extremely severe 
diabetes. The Akita mutation is an autosomal dominant mutation where heterozygous males are 
severely hyperglycemic and are used as a model for type 1 diabetes (Akita mouse). 
Hyperglycemia is pronounced in male mice where plasma glucose levels may reach as high as 
500 mg/dL, while glucose levels in female mice only reach about 280 mg/dL. In addition to 
increased plasma glucose levels, Akita mice exhibited several other diabetic symptoms 
including increased water consumption, increased appetite, increased urination, and decreased 
body weights. These symptoms are typically seen in diabetic patients prior to treatment with 
insulin. Due to the severe hyperglycemia, the untreated Akita male mice have a reduced 
lifespan to about 13 months of age. It is important to note that despite the severe hyperglycemia 
the Akita male mouse does not develop overt diabetic complications such as nephropathy 
suggesting that there is an underlying genetic factor required to induce diabetic complications. 
This model was used to induce diabetes in the presence of the Polg-D257A mutation for the 
first part of my dissertation. 
Mouse Models of Obesity and Type 2 Diabetes 
For induction of obesity and type 2 diabetes, I chose to use a well-established dietary 
model. Induction of obesity and type 2 diabetes occurs through a dietary regime high in 
carbohydrates and fat (135). The animals are fed ad libitum for 12-14 weeks that results in a 
diabetic and obesity phenotype characterized by hyperinsulinemia, hyperglycemia, and 
significant gain in weight due to the storage of fat in the subcutaneous and inguinal fat depots 
(136). The diet induced obesity leads to a sustained increase in circulating insulin that over 
time will develop the insulin resistance phenotype. Similar to Akita mice, the mice do not 
develop diabetic complications. This model was utilized in the second part of my dissertation. 
  18 
1.8 Overall Goals and Hypotheses 
The overall goals of this dissertation project were to determine the effects of artificially 
increasing mitochondrial DNA mutations on the metabolic diseases of diabetes and obesity. To 
do so, I utilized genetically engineered models of diabetes along with the PolgD257A mouse 
model for inducing an accumulation of mitochondrial DNA mutations. The work presented in 
Chapter 2 explores the role of increasing mitochondrial DNA mutations on both diabetes and 
diabetic complications. The expectation being that increasing mitochondrial DNA mutations 
would accelerate diabetes and diabetes-related complications. Surprisingly, the diabetic 
phenotype of the double mutant mice becomes less severe as they age. Chapter 3 characterizes 
the effect of the PolgD257A mutation on the small intestine. These experiments demonstrate 
the effects of the PolgD257A mutation on the cell cycle in the small intestine transit amplifying 
cells. Chapter 4 builds on this by uncovering the functional aspect of the cell cycle changes in 
the small intestine of PolgD257A mice. Again surprisingly, the PolgD257A mice fed a normal 
diet do not experience any outward phenotype, however after given a diet high in 
carbohydrates and fat the PolgD257A mice do not become obese and they are protected against 
high-fat diet induced metabolic dysfunction. 
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C h a p t e r  2  
THE MITOCHONDRIAL DNA POLYMERASE EDITING MUTATION, POLGD257A, 
REDUCES THE DIABETIC PHENOTYPE OF AKITA MALE MICE BY SUPPRESSING 
APPETITE 
©2011 National Academy of Sciences, USA. 
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2.1 Abstract 
Diabetes and the development of its complications have been associated with 
mitochondrial DNA (mtDNA) dysfunction, but causal relationships remain undetermined. 
With the objective of testing whether increased mtDNA mutations exacerbate the diabetic 
phenotype, I have compared mice heterozygous for the Akita diabetogenic mutation (Akita) 
with mice homozygous for the D257A mutation in mitochondrial DNA polymerase gamma 
(Polg) or with mice having both mutations (Polg-Akita). The Polg-D257A protein is defective 
in proofreading and increases mtDNA mutations. At 3-months of age, the Polg-Akita and Akita 
male mice were equally hyperglycemic.  Unexpectedly, as the Polg-Akita males aged to 9 
months, their diabetic symptoms decreased. Thus, their hyperglycemia, hyperphagia, and urine 
output declined significantly. The decrease in their food intake was accompanied by increased 
plasma leptin and decreased plasma ghrelin, while hypothalamic expression of the orexic gene, 
neuropeptide Y, was lower and expression of the anorexic gene, proopiomelanocortin, was 
higher. Testis function progressively worsened with age in the double mutants, and plasma 
testosterone levels in 9-month old Polg-Akita males were significantly reduced compared to 
Akita males. The hyperglycemia and hyperphagia returned in aged Polg-Akita males after 
testosterone administration. Hyperglycemia-associated distal tubular damage in the kidney also 
returned, and Polg-D257A-associated proximal tubular damage was enhanced. The mild 
diabetes of female Akita mice was not affected by the Polg-D257A mutation. I conclude that 
reduced diabetic symptoms of aging Polg-Akita male mice results from appetite suppression 
triggered by decreased testosterone associated with damage to the Leydig cells of the testis. 
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2.2 Introduction 
Diabetes mellitus is becoming increasingly common worldwide. A large body of data 
demonstrates links between mitochondrial dysfunction, insulin resistance, and diabetes (1, 2). 
Deleterious mitochondrial DNA (mtDNA) mutations have their greatest effect in cells that 
require high energy production, or already have high oxidative stress, including neurons, hair 
cells of the inner ears, heart and skeletal myocytes, pancreatic beta cells, as well as gut and 
kidney epithelial cells (3-9). Complications of diabetes also involve damage to these 
metabolically active cell types, leading to a hypothesis that mtDNA mutations contribute to the 
complications. Consistent with this, our lab has previously demonstrated in mice that a genetic 
absence of the bradykinin B2 receptor (B2R) combined with diabetes caused by the Akita 
mutation, Ins2C96Y, progressively increases modifications to kidney mtDNA, including 8-
hydroxy-2’-deoxyguanosine content, point mutations, and deletions (3, 4). The mtDNA 
mutations in these mice are also associated with enhanced nephropathy and senescence-related 
phenotypes in multiple tissues (3, 4). However, it remains unclear whether the mtDNA 
mutations act causally with respect to diabetes and its complications, or are consequences of 
these conditions. 
The enzymes required for mitochondrial biogenesis are encoded in the nuclear genome, 
including mtDNA polymerase gamma (Polg), which replicates and proofreads the 
mitochondrial genome. Polg is essential for life, and its complete absence leads to early 
embryonic death (10). An amino acid substitution, D257A, in the exonuclease domain II of 
Polg ablates proofreading without significantly affecting the capacity of the polymerase to 
replicate mtDNA (11, 12). Mice homozygous for the D257A mutation (Polg) die prematurely 
by 13 months of age displaying a series of aging-associated phenotypes due to increased 
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random accumulations of mtDNA mutations which lead to increased apoptosis particularly in 
tissues containing cells that are metabolically active (11, 12). The D257A mutation, which does 
not itself induce diabetes, consequently provides a tool that can be used to determine whether 
an increased frequency of mtDNA mutations can influence the pathophysiology of diabetes 
and its complications. 
In the present work, I take advantage of this tool to examine the effects of the Polg-
D257A mutation in mice that are diabetic because of the dominant Akita mutation (Ins2C96Y) in 
the Ins2 gene. The C96Y mutation prevents the formation of an important disulfide bond in 
insulin and leads to mis-folding of the protein. The mis-folded protein has impaired transport 
through the endoplasmic reticulum (ER), which triggers an ER stress reaction leading to 
pancreatic β cell apoptosis (13). Males heterozygous for the Akita mutation, but not females, 
develop hyperglycemia beginning at around 3 weeks of age and becoming progressively more 
severe with age. Surprisingly, our experiments show that the diabetic symptoms of Akita male 
mice which also have the PolgD257A mutation (Polg-Akita) become progressively less severe 
after 3 months age. I demonstrate that the overall improvement in the diabetic phenotype of the 
Polg-Akita mice is at least in part due to a reduction in the Akita-induced hyperphagia 
triggered by a Polg-induced decrease in testis production of testosterone. Glomerular changes 
were mild in all the diabetic mice. Proximal tubular damage occurred only in aged double 
mutant males. Distal tubular damage occurred in all hyperglycemic males.  
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2.3 Methods 
Mice. All mice were maintained on normal chow containing 5.3% fat and 0.019% cholesterol 
(Prolab Isopro RMH 3000, ref 5P76; Agway Inc., Syracuse, NY, USA). The experimental 
animals were Akita heterozygous males homozygous for the PolgD257A mutation. Controls were 
male Akita littermates that were either wild type at the Polg locus (Polg+/+Akita) or 
heterozygous for the mutation (PolgD257A/+Akita). Heterozygous PolgD257A mutants are 
phenotypically indistinguishable from wild type mice (11). Both male and female animals were 
monitored for diabetes and characterized at 3, 6, and 9 months of age. The breeding process to 
generate doubly mutant and control mice is described in Figure 2.1. All animal experiments 
were performed in accordance with the Institutional Animal Care and Use Committee at The 
University of North Carolina at Chapel Hill. 
Plasma Analyses. Animals were fasted in the morning, 4 hrs prior to the collection of blood. 
Plasma glucose was measured using a colorimetric kit (#439-90901, Wako Chemical Co., 
Richmond, VA). Plasma levels of leptin, insulin, and ghrelin were measured using ELISA kits 
(#90030 and #90080, Crystal Chem, Inc., Downers Grove, IL and #EZRGRT-91K, LINCO 
Research, St. Charles, MO). Testosterone levels were measured in plasma pooled from 3 mice 
per sample with RIA kits (#TKTT2 Siemens Medical Solutions Diagnostics, Los Angeles, CA) 
by the Reproductive Biology Core at the University of Virginia. 
Mitochondrial DNA Mutations. Mitochondria was isolated from 200 mg of liver samples 
pooled from 3 to 5 mice of each genotype by differential centrifugation in a sucrose gradient as 
described (14).  DNA was purified using standard isolation protocols and fragmented by  
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Figure 2.1: Mouse Breeding scheme. C57BL/6J mice heterozygous for the PolgD257A mutation 
were crossed to C57BL/6J-Ins2C96Y/+ heterozygotes (Akita, #003548, Jackson Lab). (A) Multi-step 
breeding used to generate both Polg-Akita and Akita mice. Both Polg and Ins2 loci are located on 
chromosome 7. A male PolgD257A/+;Ins2+/+ mouse was crossed to a female Polg+/+; Ins2C96Y/+ mouse 
to generate PolgD257A/+;Ins2+/C96Y progeny in which the mutations are on the two parental 
chromosomes.  A second generation breeding cross was then setup between a male 
PolgD257A/+;Ins2+/C96Y mouse and a female Polg+/+;Ins2+/+ mouse. Due to crossover, both mutations 
are on the same chromosome. A third cross of a male PolgD257A/+;Ins2C96Y/+ to a female 
PolgD257A/+;Ins2+/+ mouse yields the experimental PolgD257A/D257A;Ins2C96Y/+ mice with a frequency of 
5%; slightly less than expected (6.25%) because of crossing over. (B) Adjusted breeding scheme 
used to generate additional Polg-Akita and Akita mice. The numbers in parentheses are the percent 
of male offspring with the genotype obtained from each cross. PolgD257A/D257A;Ins2C96Y/+ males 
younger than 6 mo. of age were used in scheme B. This cross eliminates any effects of crossovers, 
and ensures that the mitochondria inherited from the mother are initially normal. 
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Covaris S220 adaptive focused acoustic apparatus (MA, USA) into 300 bp in length, and 
subjected to high throughput sequencing of 5,000-27,000 reads per base using Illumina GAII.  
DNA sequence was processed through the band led Solexa image extraction pipeline and 
aligned with ELAND software against murine mitochondrial genome sequence (NCBL Build 
36) as a reference. Default quality score was adjusted to allow 2 mismatches per 36 bp reads. 
The uniquely mapped reads were used for further analyses. 
Gene Expression. Total RNA was purified from hypothalamus and pancreas samples using 
Trizol (#15596-026 Invitrogen, Carlsbad, CA) as previously described (15). Total RNA from 
other tissues was purified using an Automated Nucleic Acid Workstation ABI 6700. Real-time 
PCR was performed in an ABI PRISM 7700 Sequence Detector (Applied Biosystems, Foster 
City, CA). β-Actin mRNA was used for normalization.  
Glucose Tolerance Tests. Male mice of each genotype were fasted for 4 hrs  prior to oral 
gavage of glucose (2g/kg BW).  Plasma was collected for glucose measurement at time points 
of 0, 15, 30, 60, and 120 minutes after gavage.  
Urine Analyses. Mice were housed in metabolic cages, allowed to acclimate to the new 
environment for 24 hrs, and urine samples were collected over a second period of 24 hrs. Body 
weight, food, and water were measured before and at the end of the second period of 24 hrs. 
Urinary Albumin and creatinine were measured using kits (Albuwell, #1011 and Creatinine 
Companion, #1012 Exocell, Inc., Philadelphia, PA). Urinary levels of Na, K, and Cl were 
measured using an Automatic Chemical Analyzer (VT250, Johnson & Johnson). 
Histology. Tissues were fixed in 4% paraformaldehyde (PFA). Paraffin sections at 5 µm were 
stained with Hematoxylin and Eosin, Periodic acid-Schiff, or Masson’s Trichrome. For 
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transmission electron microscopy (JOEL USA, Inc.), small tissue fragments were post-fixed in 
2% osmium tetroxide and one-micron thick sections were stained with uranyl acetate followed 
by lead citrate. 
Testosterone Replacement.  Six month old Polg-Akita and Akita mice were implanted with 
12.5 mg/90 Day Testosterone time-release pellet (Innovative Research America, Sarasota, FL). 
This dose was shown to normalize plasma testosterone levels in orchidectomized mice (16).  
Data Analysis.  Values are reported as mean ± SEM.  Statistical analyses were conducted with 
JMP 6.0.2 software (SAS Institute, Cary, NC). P values less than 0.05 were considered 
significant.  
  40 
2.4 Results 
Mitochondrial mutations in Polg-Akita mice. The reported median lifespan of Polg mice 
homozygous for Polg-D275A mutation is 13 months, and the amount of mtDNA mutations 
accumulating in Polg mice has been estimated to be as high as 1x10-3 mutations/bp in most 
tissues compared to <5x10-4 mutations/bp in wild type mice (11, 12, 17, 18). Because untreated 
Akita diabetic mice deteriorate quickly after 9 months (19), I determined mtDNA mutation 
load in the liver of 9 month old mice, which are histologically intact at this age. As expected, 
the average number of base substitution per site per hundred mtDNA molecules, without 
correcting for errors associated with deep sequencing and heteroplasmic polymorphisms, was 
significantly higher in the Polg mice than in their wild type (WT) littermates (0.425±0.005 
mutations per site per hundred molecules sequenced versus 0.375±0.004; P ≤ 0.001). Diabetes, 
again as expected, further increased base substitution rate (P < 0.001), with the Polg-Akita 
mice having significantly more mutations than their Akita littermates (0.557±0.007 versus 
0.494±0.008; P ≤ 0.001). I conclude that the mtDNA of 9-month-old Polg-Akita mice has 
accumulated significantly more mutations than the mtDNA of their Akita siblings. 
The expressions of mitochondrial transcription factor A (Tfam), mtDNA polymerase 
gamma (Polg), and cytochrome b (CytB) have been correlated respectively with mitochondrial 
biogenesis (20), replication (21), and function (22). However, renal and hepatic gene 
expression of Tfam, Polg, and CytB did not differ significantly among the groups (Table 2.1). 
Similarly, mtDNA content in these tissues was not significantly different between the two 
genotypes (Fig. 2.2). I conclude that the Polg mutation did not change mitochondrial 
biogenesis and replication in our diabetic mice. mtDNA damage associated with diabetes also 
includes an increased incidence of deletions (3, 4). However I found no significant differences 
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Table 2.1: Renal and Hepatic Gene Expression at 9 Months of Age 
 Renal Hepatic 
 9 months 9 Months 
 WT Akita Polg-Akita WT Akita Polg-Akita 
n= 7 6 7 4 3 4 
Polg 1.00±0.19 1.06±0.28 0.98±0.15 1.00±0.07 2.55±0.65 1.00±0.10 
Tfam 1.00±0.13 0.90±0.32 1.39±0.24 1.00±0.27 1.10±0.7 0.28±0.13 
Cyb 1.00±0.08 1.28±0.28 1.32±0.13 1.00±0.25 1.70±0.38 1.00±0.18 
mRNA levels were determined by Real time PCR and expressed relative to the mean levels in 
the wild type kidneys as 1.00. Data are expressed as Mean ± SEM. No statistical differences 
were observed by Tukey-Kramer HSD. 
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Figure 2.2: Mitochondrial DNA in the liver (A, E), pancreas (B, F), kidney (C, G), and small 
intestine (D, H). DNA was isolated from tissues and Real-time PCR amplification for the 
Cytochrome b gene was performed to assay mitochondrial DNA content using amplification of the 
Na-K-Cl cotransporter 2 gene (NKCC2) as an indicator of the content of nuclear DNA. A deletion 
of ~3.8kb in relation to the D-loop of mtDNA was assayed using a primer probe set that 
recognizes the loss of the D-17 region in the mtDNA genome (A, B, C, D) Mitochondrial DNA 
content relative to genomic DNA and (E, F, G, H) D17 deletions in the pancreas, kidney, and 
small intestine, respectively, of 9 month old Akita (WA) and Polg-Akita (PA) mice. The extent of 
D-17 deletions was expressed relative to the mtDNA gene coding for Cytochrome b in each 
animal. All data are represented as Mean ± SEM. (n≥6) Numbers in the bars indicate the number 
of animals. * P < 0.05 PA versus WA. 
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in the incidence of D-17 deletions in the liver, pancreas, kidneys and small intestine of the 
Polg-Akita mice compared to the Akita mice (Fig. 2.2). 
Improved diabetic symptoms in aging male Polg-Akita mice. At 3 months of age, both 
Akita and Polg-Akita male mice exhibited all the symptoms normally associated with type 1 
diabetes. Thus, both had markedly elevated plasma glucose levels (491±33 mg/dl, Fig. 2.3A) 
and food intake (8.5g/day, Fig. 2.3B) compared to their non-diabetic counterparts. In contrast, 
at 6 months of age, plasma glucose and food consumption in the Polg-Akita mice began to 
show significant decreases relative to the Akita mice. By 9 months of age, the fasting plasma 
glucose levels in the Polg-Akita mice (280±50 mg/dL) had decreased still further compared to 
their littermate Akita mice (475±54 mg/dl), although they were still significantly higher than in 
non-diabetic wild type (167±10 mg/dL) and Polg mutant (151±10 mg/dL) mice. The food 
intake of the Polg-Akita mice was dramatically lower than that of littermate Akita mice, and 
was no longer different from that of non-diabetic mice. In contrast, the body weight of the 
Polg-Akita mice increased steadily with age, and at 9 months they were significantly heavier 
than their Akita littermates (26.3±1.2 g versus 21.6±1.2 g; P ≤ 0.01, Fig. 2.3C). The weight 
gain in the Polg-Akita mice was associated with significantly larger amounts of subcutaneous 
and visceral fat (Fig. 2.3D), although still below the amount observed in wild type mice. 
Diabetes in our female Akita mice was mild, as has been reported previously (19); it was not 
affected by the PolgD257A mutation (Fig. 2.4). Thus, plasma glucose levels are similar in Akita 
(276±15 mg/dL) and Polg-Akita females (282±20 mg/dL) through 9 months of age. Likewise, 
food consumption is similar in Akita (3.78±0.16 g/Day) and Polg-Akita females (3.71±0.27 
g/Day) through 9 months of age. Together, these data show that, starting around 3 months of 
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Figure 2.3: Amelioration of diabetic profiles in Polg-Akita mice. (A) Plasma glucose, (B) Food 
consumption, and (C) Body weight in male wild type (W), Polg (P), Akita (WA), and Polg-Akita 
(PA) mice. Gross weight of subcutaneous (SF) and visceral (VF) fat in (D) 9 months old Akita 
(WA) and Polg-Akita (PA) male mice. All data are represented as Mean ± SEM. * P < 0.05, ** P 
< 0.01, and *** P < 0.001 between Polg-Akita and Akita mice at each time point by Student’s t-
test. n ≥ 20, n ≥ 10, and n ≥ 7 at 3, 6 and 9 months, respectively. 
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Figure 2.4: Diabetes in female Akita and Polg-Akita mice. (A) Body Weight, (B) Food 
Consumption, (C) Plasma Glucose, (D) Water Consumption, (E) Urine output, and (F) 
Urinary Albumin in Akita(WA) and Polg-Akita (PA) mice at 3, 6, and 9 months of age. All 
data are represented as Mean ± SEM. * P < 0.05 indicate significant difference. 
 
 
  46 
age, the PolgD257A mutation causes an age-dependent and male-specific amelioration of the 
Akita diabetic phenotype. 
Kidney function. At 3 months of age, Polg-Akita males had small but significant decreases 
(~20%) in water consumption (Fig. 2.5A) and urine output (Fig. 2.5B) compared to Akita 
mice, although both variables were markedly higher than in non-diabetic mice. Urine glucose 
levels at 3 months of age (Fig. 2.5C) were comparable in Polg-Akita and Akita mice. However, 
as the hyperglycemia of the male Polg-Akita mice improved with age, their water 
consumption, urine output, and urinary glucose also declined, and at 9 months of age they were 
no longer different from those of non-diabetic mice. Urinary potassium, sodium, and chloride 
levels did not differ in the diabetic mice regardless of the presence of the PolgD257A mutation. 
Despite the improvement of hyperglycemia, daily urinary albumin excretion was similar in the 
Polg-Akita and Akita males although it was only modestly greater than in non-diabetic males 
throughout the 9 months of study (Fig. 2.5D).  
The glomeruli showed no notable differences between the diabetic Akita mice and the 
Polg-Akita mice under both light microscopy (Figs. 2.5E and 2.5F) and electron microscopy 
(Fig. 2.6). No evidence of fibrosis or areas of necrosis were found. In the distal tubular 
epithelial cells, glycogen deposits in the central portion of nuclei were present in both the Akita 
and Polg-Akita kidneys, but were more prominent in the Akita mice than in Polg-Akita mice 
(Figs. 2.5E, 2.5F, long arrows). In the proximal tubular epithelial cells, in contrast, cytoplasmic 
clear foamy inclusions were present only in the Polg-Akita kidneys (Fig. 2.5F, arrow heads), 
while no such changes were seen in either the Akita kidneys or in non-diabetic Polg kidneys of 
the same age. Ultra-structurally, the foamy cytoplasmic inclusions seen by light microscopy in 
the proximal tubular cells of the Polg-Akita kidneys proved to be markedly enlarged lysosomes 
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Figure 2.5: Renal function and histology in 9-month-old Polg-Akita mice. (A) Water consumption, (B) 
urine output, (C) urine glucose, and (D) urinary albumin in Wild type (W), Polg (P), Akita (WA), and Polg-
Akita (PA) mice. Renal histology of diabetic (E) Akita and (F) Polg-Akita mice with proximal tubules (blue 
outline) and distal tubules (yellow outline). (G) Electron micrograph of Akita distal tubular cells with 
glycogen deposits (yellow arrow heads) within the nuclei. (H) Electron micrograph Polg-Akita proximal 
tubular cells with mitochondria and lamellated inclusions (blue arrow heads) in the cytoplasm. All data are 
represented as Mean ± SEM. * P < 0.05 and *** P < 0.001 between Polg-Akita and Akita mice at each time 
point by Student’s t-test. n ≥ 6 at 3, 6 and 9 months. 
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Figure 2.6: Kidney electron micrographs of Akita and Polg-Akita. Glomeruli of (A) Akita mice 
and (B) Polg-Akita mice show no discernible differences in glomerular basement membrane and 
podocyte morphology. The proximal tubular cells of Polg-Akita kidneys (C, outlined in blue) 
contain lamellated inclusions (blue arrow heads) throughout the cytoplasm. The distal tubular cells 
(D, outlined in yellow) appear normal with normal nuclei appearance (yellow arrow heads). In this 
section of proximal tubular cells from Polg-Akita supplemented with testosterone for 90 days (E, 
outlined in blue) show a marked increase in lamellated inclusion bodies (blue arrow heads) 
compared to un-supplemented Polg-Akita kidneys (C). Like wise, the distal tubular cells form Polg-
Akita supplemented with testosterone (F, outlined in yellow) shows a marked increase in glycogen 
deposits in the nuclei (yellow arrow heads) compared to un-supplemented Polg-Akita kidneys (D). 
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containing electron-dense material and calcifications (Fig. 2.5H). Lamellated inclusions of 
glycolipids in lysosomes are correlated with increased damage and turnover of mitochondria 
within cells, and some inclusions can be seen in Polg-Akita kidneys, although most of the 
mitochondria appeared normal except for some variations in sizes and density. No inclusions 
were seen in the Akita littermates (Fig. 2.5G). Taken together, these data show that the distal 
renal tubular damage, which occurs in the Akita mice in association with their severe 
hyperglycemia, disappears in the Polg-Akita mice, in association with their markedly 
decreased hyperglycemia, but proximal tubular damage is now apparent because of 
mitochondrial damage caused by the Polg mutation. 
Plasma insulin and insulin sensitivity. Insulin mRNA amounts in the pancreas of both Akita 
and Polg-Akita mice were similar, at 20–30% of the levels in non-diabetic wild type mice (Fig. 
2.7A). Plasma insulin levels in the Akita and Polg-Akita mice were also approximately 20% of 
those in non-diabetic mice. Plasma insulin levels in the Polg-Akita mice were slightly higher 
than those in the Akita littermates, but the difference was not significant (Fig. 2.7B). No 
differences in the morphology and numbers of pancreatic islet cells were found between the 
Akita (Fig. 2.7C) and Polg-Akita (Fig. 2.7D) mice. At 9 months, both the Akita and Polg-Akita 
males exhibited impaired clearance of oral glucose loads (Fig. 2.7E). However, plasma insulin 
levels after the oral glucose challenge did not differ significantly in the Akita and Polg-Akita 
mice (Fig 2.7F). Taken together, these data demonstrate that adding the PolgD257A mutation did 
not significantly change the already impaired beta-cell function of the Akita mice, and that the 
impaired glucose handling exhibited by the Akita mice was likewise not changed by the Polg 
mutation. 
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Figure 2.7: Insulin levels in Akita and Polg-Akita mice. (A) Insulin mRNA levels and (B) 
Plasma insulin in wild type (W), Akita (WA), and Polg-Akita (PA) mice at 6 and 9 months of age. 
All data are represented as Mean ± SEM. (C) Pancreas (H&E) from 9-month-old Akita and (D) 
Polg-Akita mice. (E) Glucose tolerance test (GTT) and (F) plasma insulin during GTT at 9 months 
of age in W, WA, and PA. ** P < 0.01 between Polg-Akita and Akita, *** P < 0.001 compared to 
wild type by Student’s t-test. 
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Small intestine function.  In agreement with a previous report (11), I find that the PolgD257A 
mutation causes an increase in apoptosis within the villi of the small intestine of the Polg-Akita 
mice relative to Akita mice. Additionally, I find an increase in apoptosis and a decrease in cell 
proliferation in the small intestine crypts of the Polg-Akita mice relative to Akita mice (Fig. 
2.8). However, these profiles were found at similar levels in non-diabetic Polg  mice, indicating 
that these PolgD257A effects were not altered by diabetes. In agreement with this, the gross 
morphology of the small intestine remained unchanged in 9-month old Polg-Akita mice 
relative to Akita mice. The mRNA levels of intestinal transporters that affect glucose uptake 
were also similar in the Polg-Akita and Akita mice (Table 2.2). Pancreatic expression of 
mRNAs for amylase, trypsinogen, chymotrypsinogen, and lipase in 9-month old Polg-Akita 
mice was not significantly affected by the PolgD257A mutation (Fig. 2.8). Taken together, these 
observations show that the Polg-Akita mice at 9 months of age display no significant 
indications of digestive problems or nutrient mal-absorption that might account for the 
amelioration of their diabetic hyperphagia and hyperglycemia. 
Appetite control. Prompted by the decrease in food consumption which developed in the 
Polg-Akita mice as they aged, I measured two known regulators of appetite: leptin (a 
suppressor of appetite) and ghrelin (a stimulator of appetite). At 9 months of age, the plasma 
leptin levels in Polg-Akita mice were significantly higher (Fig. 2.9A), while circulating ghrelin 
levels were significantly lower, relative to Akita littermates (Fig. 2.9B). Expression in the 
hypothalamus of the anorexic gene, Pomc (coding for proopiomelanocortin), and the orexic 
gene, Npy (coding for Neuropeptide Y), are critical for controlling appetite (23), and I found 
that hypothalamic expression of the orexic Npy gene was significantly increased in Akita 
diabetic mice relative to non-diabetic wild type mice (Fig. 2.9C), while expression of the 
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Figure 2.8: Polg-D257A mutation affects small intestine apoptosis and proliferation. Small 
intestines were isolated, flushed with 10mls of ice cold PBS and fixed in 4% paraformaldehyde 
at 4oC for at least 24 hours. Intestines were then cut length wise and rolled for sectioning. 
Apoptosis was evaluated using a commercially available kit (ApopTag S7110; Chemicon Int.).  
Proliferation was determined using a commercially available kit (Click-iT EdU C10084, 
Molecular Probes, Inc., Eugene, OR). The small intestine of 9 month old (A) Akita and (B) 
Polg-Akita mice were stained using the TUNEL assay for apoptosis. Cellular proliferation by 
EdU staining of the intestinal crypts from 9 months old mice comparing (C) Akita and (D) Polg-
Akita small intestines. (E) Quantification of apoptotic cells in the crypt region of the small 
intestine for wild type, Polg, Akita, and Polg-Akita. Increased apoptotic cells in the crypts were 
evident in Polg-Akita intestines. (F) Quantification of proliferating cells in the crypt region of 
the small intestine for wild type, Polg, Akita, and Polg-Akita. Decreased proliferating cells in 
the crypts were evident in Polg-Akita intestines. Pancreatic gene expression of digestive 
enzymes at 9 months of age (G) in W (wild type), WA (Akita), and PA (Polg-Akita) mice. All 
data are represented as Mean ± SEM. * P < 0.05 and *** P < 0.001 indicate significant 
difference in Polg-Akita compared to Akita mice and wild type compared to Polg mice by 
Tukey-Kramer HSD. 
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Table 2.2: Gene Expression in Small Intestine of Glucose Transporters at 9 Months of 
Age 
 WT Polg Akita Polg-Akita 
n= 5 4 4 6 
NaK ATPase α1 1.00±0.30 0.85±0.09 0.87±0.50 1.08±0.35 
NaK ATPase β1 1.00±0.37 0.73±0.17 0.67±0.24 0.76±0.20 
Glut2 1.00±0.23 0.26±0.11 0.82±0.42 0.45±0.08 
Sglt 1.00±0.29 0.86±0.19 0.87±0.43 0.70±0.20 
mRNA levels were determined by Real time PCR and expressed relative to the mean levels in 
the wild type intestines as 1.00. Data are expressed as Mean ± SEM. No statistical differences 
were observed by Tukey-Kramer HSD. 
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Figure 2.9: Appetite. (A) Plasma leptin, (B) plasma ghrelin, and hypothalamic gene 
expression of (C) Neuropeptide Y and (D) Proopiomelanocortin in wild type (W), Akita 
(WA), and Polg-Akita (PA) mice at 9 months of age. All data are represented as Mean ± 
SEM. * P < 0.05 and *** P < 0.001 indicate significant difference by Student’s t-test. 
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anorexic Pomc gene was significantly decreased (Fig. 2.9D). However, in the Polg-Akita mice 
these diabetes-associated shifts in Npy and Pomc expression were reversed, returning to levels 
not significantly different from those in non-diabetic wild type mice. Thus, adding the 
PolgD257A mutation to the Akita mutation increases plasma leptin, decreases plasma ghrelin, 
decreases hypothalamic expression of Npy and increases hypothalamic expression of Pomc. It 
is likely that these changes in modulators of food intake, all known to suppress appetite, result 
in the decreased appetite I observed in Polg-Akita mice relative to Akita mice. 
Testicular function. The testis is severely affected by the PolgD257A mutation (11), but not by 
diabetes. Thus, light microscopy showed that the testes of 9-month-old Akita mice (Fig. 2.10C) 
were not notably different from those of non-diabetic wild type mice (Fig. 2.10A). In contrast, 
the seminiferous tubules of the Polg (Fig. 2.10B) and Polg-Akita (Fig. 2.10D) mice were 
severely atrophic and contained vacuoles. Marked loss of germ cells and spermatogenesis was 
evident within the seminiferous tubules of both Polg and Polg-Akita mice. Light microscopy 
showed a significant increase in the number of Leydig cells per cluster in the Polg mice relative 
to WT and in the Polg-Akita mice relative to Akita, although the increase was less in the 
diabetic mice (Fig. 2.10E). Ultra-structurally, Leydig cells of the testis in Polg-Akita mice have 
a markedly degenerative morphology compared to Akita mice, including the presence of 
lipofuscin indicative of mitochondrial damage (Fig. 2.11). 
 Plasma testosterone in wild type mice at 9 months of age was 220±12 ng/dL. Plasma 
testosterone in the Akita mice was not demonstrably different from this at 6 months age, but 
had decreased to about 50ng/dL at 9 months age (Fig. 2.10F). The Polg-Akita mice had 
significantly lower plasma testosterone levels than the Akita mice at both ages (~30%; P < 
0.01). Together, these data demonstrate that the PolgD257A mutation has a strong and direct 
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Figure 2.10: Diminished testis function in Polg-Akita mice. Comparable histology 
sections of the testis of 9 month old (A) Wild type - W, (B) Polg - P, (C) Akita - WA 
and (D) Polg-Akita - PA mice. (E) Total number of cells/ Leydig cluster and (F) plasma 
testosterone. All data are represented as Mean ± SEM. * P < 0.05, ** P < 0.01, and *** 
P < 0.001 indicate significant difference by Student’s t-test. 
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Figure 2.11: EM of Leydig cells.  
(A, C) Akita – The Leydig cell clusters are composed of tightly packed cells that have short 
villi on the cell surface. The nuclei are oval to angulated and have marginated chromatin. Nearly 
all cells contain lipid droplets (small round clear spaces) in the cell cytoplasm and a few contain 
lipofuscin deposits (A, Arrows). One Leydig cell appears to contain a small lumen within the 
cytoplasm (C, yellow arrow). Other cells contain whorled aggregates of smooth endoplasmic 
reticulum (C, yellow arrow heads).  
(B, D) Polg-Akita – In this cluster of Leydig cells, the cells are loosely aggregated and the 
cytoplasm of some cells contains lipid droplets. The cells have an angulated shape with 
chromatin clumps and thin marginated chromatin.  Lipofuscin is present within the cytoplasm 
(black arrow heads). Poorly formed whorles of smooth endoplasmic reticulum are present (D, 
black arrows). (Although not shown in this photograph, the amount of collagen within the 
Leydig cell clusters appeared to be increased in Polg-Akita mice.) 
Note: There are also some additional findings in the Leydig cells that are shown in these 
photographs but are less clear. These are the “whorled” arrangements of endoplasmic reticulum. 
These were present more often in Leydig cells from PP and Polg-Akita. The mitochondria in all 
mice appeared to be similar in number and size. 
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negative impact on testosterone levels and testicular function in the Polg-Akita mice. 
Testosterone replacement. To test whether decreased testosterone levels are responsible for 
the reduced appetite and hyperglycemia, I implanted pellets into 6-month old Polg-Akita mice 
(n=3) that deliver the physiological dose of testosterone (0.14mg/day) commonly used in 
replacement therapy in mice (16). Within 15 days after implantation of the testosterone pellet, 
plasma glucose in the Polg-Akita mice increased from 300 mg/dl to 500 mg/dl, 
indistinguishable from the level in Akita mice without testosterone supplementation (Fig. 
2.12A). Their food consumption also increased compared to untreated Polg-Akita mice, and 
were essentially the same level as in untreated Akita mice (Fig. 2.12B).  Taken together, these 
data show that testosterone is a key component that directly regulates food consumption and 
thereby influences the hyperglycemia of Akita male mice.  Surprisingly, however, despite the 
return of hyperglycemia in the Polg-Akita mice treated with testosterone, their daily urine 
output, glucose excretion and urine albumin excretion were not increased (Figs. 2.12C-E). This 
indicates that the testosterone treated Polg-Akita mice are reabsorbing substantial amounts of 
glucose, and suggested to us that the kidneys of these animals were likely to be metabolically 
stressed. In support of this idea, I found that the ultrastructure of the proximal tubules of the 
Polg-Akita mice treated with testosterone for 3 months showed considerably more lamellated 
inclusions (Fig. 2.6E) than were present in the untreated Polg-Akita mice of the same age (Fig. 
2.6C). 
  59 
Figure 2.12: Testosterone replacement in Polg-Akita mice. (A) Plasma glucose levels in 
Testosterone implanted Akita (WA+T) and Polg-Akita (PA+T) mice and Control Akita (WA or 
WA-T) and Polg-Akita (PA or PA-T). (B)Food Consumption, (C) Urine Volume, (D) Urine 
Albumin, and (E) Urine Glucose in WA, PA, and PA-T at 22 days post implant. All data are 
represented as Mean ± SEM. Scale bar=100µm * P < 0.05, ** P < 0.01, and *** P < 0.001 
indicate significant difference by Student’s t-test.  
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2.5 Discussion 
Because of the importance of mitochondria in metabolism, I expected that the PolgD257A 
mutation, which leads to an accumulation of random mtDNA mutations, would exacerbate the 
diabetes exhibited by male Akita mice and would increase the severity of their diabetic 
complications. Surprisingly, I found the opposite result: a dramatic improvement of diabetic 
symptoms (hyperglycemia, food consumption, and water consumption) in the Polg-Akita male 
mice as they aged. Accompanying these changes, I found alterations in the expression of 
anorexic (Pomc) and orexic (Npy) genes in the hypothalamus indicating that the Polg mutation 
had caused appetite suppression. I did not find any improvement in the overall function of 
either the pancreas or small intestine that would be sufficient to alter the diabetes so markedly. 
However, there was a dramatic aging-associated increase in testicular damage in the Polg-
Akita mice relative to the Akita mice, including damage to the Leydig cells, and a reduction in 
plasma testosterone. Testosterone replacement increased food consumption in the double 
mutants, and their hyperglycemia returned, confirming the influence of testosterone and 
appetite in the development of the diabetic symptoms of Akita male mice. 
In non-diabetic animals, an increase in plasma glucose after a meal stimulates the 
release of insulin.  Insulin binds to insulin receptors in peripheral tissues and triggers glucose 
uptake via insulin-sensitive glucose transporters. Insulin, together with the amylin released by 
the beta cells simultaneously with insulin (24), plays an important role in the regulation of 
appetite by suppressing orexic genes within the hypothalamus (25, 26). In Akita mice, mis-
folded insulin protein causes ER stress and β cell death, resulting in reduced insulin production 
(13). Insufficient insulin production initiates two pathways that accelerate hyperglycemia in 
Akita mice (Fig. 2.13A). First, it reduces the ability of peripheral tissues to take up glucose. 
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Second, the reduced insulin impairs appetite suppression in the hypothalamus causing 
hyperphagia. The increased food intake induces an increased demand for insulin, which 
increases the problems of the already stressed insulin-producing β cells leading to further β cell 
death. This damaging feedback can be partly interrupted by reducing food intake, as illustrated 
by the well-documented benefits of reduced food intake in the management of type 1 diabetes 
before the discovery of insulin (27). 
In the present study, I have demonstrated that the mtDNA mutator, Polg-D257A, can 
break the self-induced cycle of hyperglycemia and hyperphagia of Akita male mice as they age 
(Fig. 2.13B). The most striking age-dependent damage in the Polg-Akita males is in the testis, 
accompanied with a decrease in circulating testosterone. Recent studies have suggested that 
aging-related reduction of food consumption may in part result from reduced testosterone and a 
consequent increase in leptin production (28). Epidemiological studies have also demonstrated 
an association between these factors (29). In addition, testosterone administration has been 
shown to suppress the elevated leptin levels in older hypogonadal men (30, 31), and 
dihydrotestosterone suppresses both leptin mRNA levels and leptin secretions in adipocytes in 
vitro (32). Leptin, produced in adipose tissues, is crucial in the regulation of appetite by 
signaling through the hypothalamus (33). Our observations in aged Polg-Akita males show the 
involvement of these factors in the changes in food consumption and appetite induced by the 
Polg mutation. Thus, as they age, Polg-Akita mice develop significant increases in plasma 
leptin, increased Pomc and decreased Npy gene expression compared to Akita males. 
Furthermore, both hyperglycemia and hyperphagia returned in Polg-Akita males after 
testosterone administration. I conclude that the age-dependent decline of testis function and 
testosterone production caused by PolgD257A underlies the reduced diabetic phenotypes of the 
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Figure 2.13: Hyperphagic model of diabetic Akita mice (A) and the mechanism of 
reversal in Polg-Akita mice (B). (A) In Akita mice, low levels of insulin no longer 
suppresses appetite, normal testosterone levels increases appetite by either directly increasing 
Npy or through suppressing leptin while ghrelin, released from the stomach, also works in 
unison with testosterone and leptin to increase appetite through the hypothalamus. (B) In 
Polg-Akita mice, low levels of insulin and amylin no longer suppresses appetite, reduced 
testosterone levels decrease appetite by either directly decreasing Npy or allowing leptin to 
suppress Npy while reduced ghrelin also reduces appetite. Red lines – appetite stimulating 
affect, blue lines – appetite suppressing affect, black lines – no change between genotypes. 
Line thickness indicates magnitude of affect.  
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 Polg-Akita mice. This interpretation is supported by a recent report that gonadectomy causes a 
marked reduction of hyperglycemia in diabetic Akita males and normalizes Pomc and Npy 
mRNA levels within their hypothalamus, and that reducing the food intake of Akita mice also 
reduces their hyperglycemia (23).  
Testosterone increases appetite in castrated rats and appears to do so independently of 
its conversion to estrogen (34). Whether testosterone acts on adipocytes to regulate production 
of leptin, circulating leptin, or directly on the genes in the hypothalamus remains to be 
elucidated. In addition, since plasma testosterone levels also declined in aged diabetic Akita 
mice without apparent loss of appetite, other factors must be also involved. For example, a 
significant reduction in circulating ghrelin works in unison with the testosterone-leptin 
mechanism to reduce appetite. I also note that this aging-related amelioration of diabetes 
caused by the PolgD257A mutation could be exaggerated in the Akita model of diabetes in which 
β cell destruction is directly tied to insulin production. Whether it is applicable to other animal 
models of diabetes remains to be determined. 
The nephropathy in our experimental diabetic Akita mice was mild, in part because of 
their C57BL/6J genetic background, which confers resistance to diabetic nephropathy (35, 36). 
Concordant with the dramatic improvement of hyperglycemia and reduced urine output, the 
Polg-Akita mice no longer had glycogen deposits in the nuclei of their distal tubular cells. 
Instead, despite the lessening of their hyperglycemia, the Polg-Akita mice now had 
abnormalities in their proximal tubular cells. Formation of enlarged lysosomes filled with 
lamellated inclusions and calcifications indicate that the increase in mtDNA mutations induced 
by the PolgD257A mutation leads to increased mitochondrial destruction in the proximal tubular 
cells, which have high-energy requirements and are highly packed with mitochondria. I note 
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that diabetes is necessary to cause the observed abnormalities in the proximal tubular epithelial 
cells, because they were not present either in non-diabetic Polg males or in mildly diabetic 
Polg-Akita females of the same age. Our observation that the urine volumes and glucose 
excretion of testosterone treated Polg-Akita mice remained low, despite a return of 
hyperglycemia, further emphasizes this interaction. Thus, the treated mice are reabsorbing 
sufficient amounts of filtered glucose to avoid osmotic diuresis and glycosuria even with 
plasma glucose levels exceeding 500mg/dL, which requires a large amount of energy. 
Accompanying this high-energy demand, I find an accumulation of laminated bodies in the 
proximal tubules of the testosterone treated hyperglycemic Polg-Akita mice exceeding that in 
the euglycemic untreated Polg-Akita mice. 
In conclusion, I have demonstrated that the mtDNA editing mutation, PolgD257A, causes 
an age-dependent reduction of the diabetic phenotype of Akita male mice. I have shown that 
this reduction is, at least in part, due to appetite suppression caused by a premature decline in 
testosterone production associated with increased damage to Leydig cells. Since female Akita 
and Polg-Akita mice are both only moderately hyperglycemic and their food consumption 
remains similar throughout 9 months of age, the Polg-D257A does not affect the severity of 
their diabetes. The accumulation of mitochondrial debris in the proximal tubules of the Polg-
Akita males, even when euglycemic, demonstrates clearly that increased mutations in mtDNA 
exacerbate the kidney pathology in untreated type 1 diabetes.  
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C h a p t e r  3  
THE EFFECT OF MITOCHONDRIAL DNA POLYMERASE EDITING MUTATION, 
POLGD257A, ON THE CELL CYCLE OF THE SMALL INTESTINE 
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3.1 Abstract 
 Changes in nutritional absorption in the intestine are an important aspect of the aging 
process yet few comprehensive studies have been carried out addressing this issue. I used 
mitochondrial DNA mutator mice homozygous for a D257A mutation in polymerase gamma 
(PolgD257A mouse) as a genetic tool to increase mitochondrial DNA mutations and answer 
questions regarding aging in the small intestine. The small intestines of relatively young 7-
month-old PolgD257A mice have morphological changes such as increased villus height/width 
and increased crypt depth/width that mimic the aged human small intestine. I find a general 
increase in apoptosis in the small intestine crypts of Lieberkühn that has not been reported or 
studied previously in aging mice, rats, or humans. Immunohistochemically, the PolgD257A 
mutants maintained the same number of actively dividing cells in the proliferating region of the 
crypt, yet cell migration along the crypt-villus axis was diminished and a lesser proportion of 
cells are in S-phase of the cell cycle than the wild type littermates. In vitro, I find that the stem 
cells from crypts proliferate at a slower rate and produce less budding via symmetric division 
in the PolgD257A mice than those in wild type mice.  I conclude that the PolgD257A mutation 
causes age-associated changes in the morphology of the small intestine correlated with 
increased apoptosis of progenitor and stem cells, a slower cell cycle in the proliferating 
progenitor cells, and a proliferation defect in the stem cells located in the crypts of Lieberkühn. 
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3.2 Introduction 
With the growing elderly population and its ramifications on the health care system, a 
clear understanding of the mechanisms behind the aging process in individual organs is 
important. Aging has been widely accepted as the root cause of organ degeneration and 
dysfunction. For instance, elderly subjects are prone to malnutrition and mal-absorption, both 
of which are associated with intestinal dysfunction (1, 2). Morphological changes in the small 
intestine villi and crypts of elderly subjects have been reported to include enlarged height and 
width of villi and crypts (3, 4). However, there are no comprehensive studies demonstrating 
how these changes in villi shape affect function. In agreement with these findings in humans, 
studies of both mice and rats have shown similar changes with age. The small intestines of 
aged rats have increased size of the villi and crypt compartments (5). A histological 
comparison between young and old mice also provides evidence for the increased size of the 
villi and crypt compartments in old mice compared to young mice (6).  
Aging of the human small intestine is also characterized by increased apoptosis and 
increased proliferation of the enterocytes (3, 7). Increased proliferation has also been associated 
with the aging rat small intestine, and apoptosis is initially high in young rats and diminishes to 
low levels in aging rats (8, 9). However, comprehensive studies on the age-related changes in 
the levels of apoptosis in the villi and crypt compartments of humans, rats, and mice are 
lacking. In addition, whether any of these morphological or molecular changes lead to 
dysfunction of the aging intestine has not been determined. 
Mitochondrial dysfunction is known to affect basic cellular function, initiate apoptosis, 
and lead to aging (10). Insertions, deletions and point mutations in the mitochondrial genome 
have their greatest effect in cells that require high energy production including neurons, hair 
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cells of the inner ears, heart and skeletal myocytes, pancreatic beta cells, as well as gut and 
kidney epithelial cells (11-15). Mitochondrial DNA mutations in the colon of elderly subjects 
have been shown to cause a decrease in cellular proliferation and an increase in apoptosis (16). 
Yet, a mechanism behind the cause of increased proliferation and decreased apoptosis has not 
been determined due to a lack of an appropriate aging model that mimics these findings in 
humans. 
Mitochondrial DNA polymerase gamma (Polg) is responsible for replicating the 
mitochondrial genome. An introduction of an amino acid substitution, D257A, in the 
exonuclease domain II disrupts the proofreading ability of Polg without significantly affecting 
the replicating capacity of the polymerase (17, 18). Mice homozygous for the PolgD257A 
mutation have a reduced lifespan of 13 months, and display a series of aging-associated 
phenotypes at 10 months of age as a consequence of increased random accumulations of 
mtDNA mutations (17, 18). These include graying and loss of hair, kyphosis, and decreased 
bone density. Hence, the homozygous PolgD257A mouse is an animal model of premature 
aging with all the visible signs of human aging.  
Previous reports have shown that several tissues in PolgD257A mice, including 
thymus, small intestine, and testes, have elevated levels of apoptosis at 3 months of age (17). 
Consequently, the D257A mutation provides a genetic tool that can be used to determine if an 
increased frequency of mtDNA mutations in the small intestine will contribute to an aging 
phenotype, including apoptosis. 
In the present work, I have investigated PolgD257A mice as a means to accelerate 
aging in the small intestine. Previous work utilizing the PolgD257A mouse has shown that the 
villi of the small intestine undergoes two distinct changes: (i) increased villi epithelial cell 
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apoptosis; and (ii) morphology changes, such as elaborate branching and fusion (17). However, 
it is not clear if the increase in apoptosis and the change in morphology of the villi causes any 
other molecular changes. How the small intestine phenotype affects the whole body 
metabolism when fed a high fat western diet is described in Chapter 4. In this chapter, I 
characterized the small intestine phenotype of 3 and 7 month old mice homozygous for the 
PolgD257A mutation, and I demonstrate that 7-month-old PolgD257A mice have 
morphological changes to the villi and crypt compartments that mimic human small intestine 
aging. Surprisingly, I found an increase in apoptosis in the small intestine crypts of Lieberkühn, 
which has not been reported in these mice. The PolgD257A mutant small intestine maintained 
the same number of cells in the proliferating region of the crypt, however cell migration along 
the crypt-villus axis was diminished and correlated with a disruption of the cell cycle. While 
morphological changes of human aging of the small intestine are similar in PolgD257A mice, 
the changes in the cell cycle and apoptosis found in the crypts are novel findings in the context 
of premature aging.
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3.3 Materials and Methods 
Mice. All mice were maintained on normal chow containing 5.3% fat and 0.019% cholesterol 
(Prolab Isopro RMH 3000, ref 5P76; Agway Inc., Syracuse, NY, USA). The experimental 
animals were males homozygous for the PolgD257A mutation that have been extensively 
backcrossed onto a C57BL/6 background. Littermate controls were wild type at the Polg locus. 
Male animals were monitored and characterized at 3 and 7 months of age. All animal 
experiments were performed in accordance with the Institutional Animal Care and Use 
Committee at The University of North Carolina at Chapel Hill. 
Isolation of Small Intestines. Mice were lethally anesthetized animals with an over dose of 
2,2,2 Tribromoethanol and the small intestine was removed from the stomach to the cecum of 
the large intestine. Isolated intestines were placed in ice cold PBS, and subsequently flushed 
with 10 mLs of ice cold PBS.  The intestines were split into two sections, duodenum to 
jejunum and jejunum to ileum.  Each section was placed in 4% paraformaldehyde at 4°C for at 
least 24 hours.  Intestines were then cut length wise and rolled for sectioning.  
Histology. Paraffin sections were cut at a thickness of 5 µm and stained with Hematoxylin and 
Eosin, Periodic acid-Schiff, or Masson’s Trichrome. Analysis of villus length & width, crypt 
length & width, intestinal length, and intestinal diameter were measured on digitally scanned 
slides using ImageScope Software. 
Apoptosis and S-Phase Detection. Terminal deoxynucleotidyl transferase dUTP nick end 
labeling (TUNEL) was used to detect DNA fragmentation caused by apoptosis signaling. A 
commercially available TUNEL kit was used to determine apoptosis (ApopTag S7110; 
Chemicon Int.). To determine cells in S-phase, animals were injected with 50 µg/ml of 5-
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ethynyl-2´-deoxyuridine (EdU) and sacrificed 2 hours after injection. Cells in S-Phase were 
determined as previously described (19) using a commercially available kit (Click-iT EdU 
C10084, Molecular Probes, Inc., Eugene, OR). 
Cell Migration. For EdU pulse time course, mice were injected once with 50 µg/ml of EdU. 
Mice were sacrificed at 2, 24, and 48 hours after injection. For EdU washout time course, mice 
were injected 3 times per day for 4 consecutive days with 75 µg/ml EdU. Mice were sacrificed 
at 2, 24, 48, and 96 hours after the last injection. EdU was detected as described previously. 
Cell Cycle Immunostaining. Small intestine was resected, flushed of fecal contents with ice 
cold PBS, cut open along the longitudinal axis, and fixed in 4% paraformaldehyde for 16 hours 
at 4 °C. Prior to immunostaining, the sections underwent antigen retrieval using Reveal 
Decloaker (Biocare Medical, Concord, CA) in a pressure cooker set at 120°C for 30 seconds 
and then 90°C for 30 seconds. The sections were allowed to cool in the Reveal Decloaker for 
20 minutes at room temperature and washed three times with excess water for 2 minutes each. 
The sections were stained first for EdU as described above using Alexafluor 488 azide, and 
then blocked with DAKO Blocking Solution (DAKO, X0909, Carpinteria, CA) for 5 minutes 
prior to antibody staining. All primary antibodies were diluted in DAKO Antibody Diluent 
(Dako, S0809). For all proliferating cells, sections were stained with KI67 (1:500; Dako, 
#M7249). For mitosis, sections were stained with Anti-phospho Histone H3 (1:500; Ser10, 06-
570, Millipore, Temecula, CA) Cells at G1 phase were visualized with Anti-Minichromosome 
maintenance 2 (1:200; MCM2, N-19, SC-9839, Santa Cruz Biotechnology, Santa Cruz, CA). 
All primary antibodies were incubated with tissue at 4°C for 16 hours. The tissues were then 
washed three times with Tris-wash buffer (0.05 M, pH7.6) for 3 minutes each wash. Secondary 
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antibodies (Ki67: donkey anti-rat biotinylated, 712-067-003/streptavidin-405, 016-470-084; 
PH3: donkey anti-rabbit-dylight 549, 711-505-152; MCM2: donkey anti-goat-dylight 647, 705-
496-147) conjugated to fluorophores that facilitated co-localization were diluted in DAKO 
diluent at 1:250, and applied to tissue sections for 45 minutes at 21°C. The tissues were then 
washed three times with Tris-wash buffer for 3 minutes each. For nuclear staining, Bis-
benzimide (Sigma, B2883, St. Louis, MO) was diluted to 5 µg/ml in Tris-wash buffer and 
applied to tissue sections for 5 minutes. The tissue was then washed once with Tris-wash 
buffer, and cover slip was mounted with Hydromount (National Diagnostics, HS-106, Atlanta, 
GA).  
Crypt Isolation, IESC FACS Enrichment, and Culturing. Crypts were isolated as 
previously described (20). The crypts were placed in crypt culturing medium (Advanced 
DMEM/F12 (Gibco, #12634) supplemented with 1X B27 w/o Vitamin A (Invitrogen # 
12587010), 1X N2 (Invitrogen # 17502048), 10 mM HEPES (Gibco # 15630-106), 100 µg/mL 
Penicillin/Streptomycin, 2 mM L-Glutamine), and 10 µl were counted to determine the 
concentration of crypts/ml of solution. A volume containing five-hundred crypts was removed 
and pelleted at 500 x g for 5 minutes at 4°C.  The medium was removed and the crypt pellet 
was lightly and carefully resuspended in 5 µl of crypt culturing medium. Matrigel culturing 
conditions were conducted essentially as described (20) with the exception that whole crypts 
were placed in 50 µl of Matrigel containing R-spondin (1 µg/mL first day, 500 ng/mL 
thereafter), Noggin (100 ng/mL, Peprotech, Rocky Hill, New Jersey, #250-38), EGF (50 
ng/mL), Jagged (1µM), and Wnt-3a (2.5 ng/mL, first day only, R&D Systems, #1324-
WN/CF).  
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 For FACS, intestinal epithelium was isolated and dissociated to single cells as 
described (20). Single cell preparations were stained in crypt culture medium with antibodies 
that would facilitate the enrichment of CD44+ IESCs. Doublets were discriminated and 
excluded using SSC-Height and SSC-Area parameters. CD45 lymphocytes and CD31 
endothelial cells were excluded using antibodies against these cell surface proteins and 
subsequent FACS exclusion gating (1:500; CD45, Biolegend; San Diego, CA); 1:500; CD31, 
Biolegend). Anti-CD44 (1:1000, Biolegend) was used to enrich the CD31-CD45- fraction for 
CD44+ IESCs. Cells that underwent downstream applications were sorted into crypt culturing 
medium that was maintained on ice for the 1 hour FACS sort period. ATP was measured using 
the CellTiter-Glo Luminescent Cell Viability Assay per manufacturer’s instructions (G7570, 
Promega Corporation, Madison, WI). 
Data Analysis.  Values are reported as mean ± SEM.  Statistical analyses were conducted with 
JMP 6.0.2 software (SAS Institute, Cary, NC). P values less than 0.05 were considered 
significant.
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3.4 Results 
Cell Apoptosis and Proliferation in the Small intestines of PolgD257A Mice. At 7 months 
of age, both wild type mice (Fig. 3.1A) and PolgD257A mice (Fig. 3.1B) have apoptosis in the 
epithelial cells found in the tips of the villi. I confirmed the previous report (17) that epithelial 
cells in the column of the villi of PolgD257A mice contain significantly increased apoptotic 
cells compared to wild type mice (Fig. 3.1B). Quantification of the apoptotic cells of the villus 
indicates a two-fold increase in cell death in PolgD257A mice (19.4 ± 1.2 cells/villus) 
compared to wild type mice (9.9 ± 1.0 cells/villus, Fig. 3.1C). Interestingly, PolgD257A mice 
showed a significant increase in apoptosis found within the crypts of Lieberkuhn (indicated by 
yellow arrowheads in Fig. 3.1B), where both intestinal stem cells and progenitor cells are 
present. High magnification (40x) of the crypts of Lieberkühn reveals a low level of apoptosis 
in wild type mice (Fig. 3.2A) compared to the increases seen in PolgD257A mice (Fig. 3.2B). 
Quantification of the apoptotic crypt cells indicates a ten-fold increase in cell death in 
PolgD257A mice (3.8 ± 0.5 cells/crypt) compared to wild type mice (0.4 ± 0.06 cells/crypt, 
Fig. 3.2E). 
EdU is incorporated into DNA during the S-phase of the cell cycle and represents a 
marker of cell proliferation. In a marked contrast, visualization of EdU was more robust in the 
crypt region of wild type mice than in PolgD257A mice. The number of EdU labeled cells in 
the crypts of Lieberkühn was significantly less in PolgD257A (5.2 ± 1.3 cells/crypt, Fig. 3.2C) 
mice than in wild type mice (13.8 ± 1.2 cells/crypt, Fig. 3.2D) demonstrating a reduction in S-
phase cell proliferation. Similar degrees of increase in apoptotic cells and decrease in 
proliferating cells were observed in the crypts of 3-month-old PolgD257A mice. From this 
data, I also conclude that the PolgD257A mutation is associated with a dramatic increase in 
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Figure 3.1: Apoptosis in wild type and PolgD257A small intestines. (A) wild type small 
intestine with apoptosis located at tip of each villus with large yellow arrows indicating 
apoptotic cells. (B) Polg small intestines have similar levels of apoptosis at the tip of each villus 
indicated with large yellow arrows. Small yellow arrows indicate an increase in apoptotic cells 
in the columnar epithelial cells along the  length of the villi. An increase in apoptosis was found 
at the basis of the villi in the crypts of Lieberkühn. (C) Quantification of apoptosis found in the 
villi. All data are represented as Mean ± SEM. ** P < 0.01 between WT (n = 11) and Polg (n = 
8) by Student’s t-test. Nuclei staining – blue and Apoptosis – green 
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Figure 3.2: Apoptosis and S-phase proliferation in wild type and PolgD257A crypts of 
Lieberkuhn.  Apoptosis is located in the region of the transit amplifying cells of wild type 
(A) and Polg (B) crypts. Wild type crypts have few apoptotic cells in this region while Polg 
mice have numerous apoptotic cells. EdU incorporation in S-phase cells in the transit 
amplifying region is found in the crypts of wild type (C) and Polg (D) mice. Wild type mice 
have numerous and robust staining of S-phase cells in this region while Polg mice have 
fewer and less intense staining of S-phase cells in this region. Quantification of apoptotic 
cells per crypt (E) and S-phase proliferating cells per crypt (F) comparing wild type and 
Polg mice. All data are represented as Mean ± SEM. *** P < 0.001 between WT (n ≥ 8) and 
Polg (n = 8) by Student’s t-test. Nuclei staining – blue, Apoptosis – green, and S-phase cells 
– yellow 
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apoptosis and a decrease in cell proliferation particularly in the crypts of Lieberkühn. 
Intestinal Cell Migration. To test whether the change in cell proliferation alters migration in 
the intestine, I conducted a pulse study with EdU in both wild type and PolgD257A mice and 
followed the migration of the labeled cells 2 hrs, 24 hrs, and 48 hrs after injection. EdU labeled 
intestinal epithelial cells of wild type mice were robustly labeled and displayed a highly 
coordinated migration pattern at 2 hrs (Fig. 3.3A), 24 hrs (Fig. 3.3B), and 48 hrs (Fig. 3.3C) 
post injection. In contrast, the EdU labeled intestinal epithelial cells of PolgD257A mice were 
sparsely labeled and displayed a random migration pattern at 2 hrs (Fig. 3.3D), 24 hrs (Fig. 
3.3E), and 48 hrs (Fig. 3.3F) post injection. The epithelial cells in PolgD257A mice are clearly 
migrating at a slower rate than in wild type mice. At 48 hrs post injection, cell migration was 
measured by the distance from the base of the crypt to the nearest EdU labeled cell. I found a 
significant reduction in epithelial cell migration in PolgD257A mice (median distance of 
migration 260 ± 4.6 µm) compared to wild type mice (median distance of migration 343 ± 3.4 
µm, Fig. 3.3G, P < 0.001). Furthermore, the lack of robust labeling in 2 hrs post injection 
PolgD257A sections is suggestive of slower DNA synthesis during the cell cycle. 
To confirm a delayed cell migration of PolgD257A intestinal epithelial cells, 
PolgD257A and wild type mice were injected with EdU three times per day for four 
consecutive days. The EdU labeled cells were followed at 2, 24, 48, and 96 hrs after the last 
EdU injection. The epithelial cells of wild type mice were completely labeled 2 hrs post 
injection by this method (Fig. 3.4A) whereas the epithelial cells of PolgD257A mice were 
labeled in the lower two thirds of the crypt-villus axis but sparsely labeled the cells at the tips 
of the villi (Fig. 3.4E). At 24 hrs post-injection, labeled wild type epithelial cells had 
completely migrated out of the crypts and started to migrate up the villi (Fig. 3.4B) whereas 
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most of the PolgD257A epithelial cells migrated out of the crypts but not up the villi (Fig. 
3.4F). At 48 hrs post-injection, labeled wild type epithelial cells had migrated half way up the 
villi (Fig. 3.4C), whereas the PolgD257A epithelial cells migrated out of the crypts and started 
to migrate up the villi (Fig. 3.4G). The labeled PolgD257A section at 48 hrs post-injection had 
the same pattern as the labeled wild type sections at 24 hrs post-injection. At 96 hrs post-
injection, labeled wild type epithelial cells had completely migrated out of the villi and were no 
longer visible (Fig. 3.4D). In contrast, labeled PolgD257A epithelial cells still remained near 
the distal end of the villi (Fig. 3.4H). Taken together, these data show that the epithelial cell 
migration in the small intestines of PolgD257A mice is significantly impaired compared to 
wild type mice.  
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Figure 3.3: Cell migration by EdU pulse is reduced in PolgD257A small intestines. 
Migration of EdU labeled cells at 2 hrs. post-injection in wild type (A) and Polg (D), 24 hrs. 
post-injection in wild type (B) and Polg (E), and 48hrs post-injection in wild type (C) and Polg 
(F). At 48 hrs post-injection of EdU, the length of migrating cells were measured from the base 
of the crypt to the first labeled cell in each villus. All data are represented as Mean ± SEM. 
Nuclei staining – blue and S-phase cells – yellow 
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Figure 3.4: Cell migration by EdU washout is slower in PolgD257A small intestines. 
Animals were injected with EdU three times per day for four consecutive days. Migration of 
EdU labeled cells at 2 hrs. post-injection in wild type (A) and Polg (E), 24 hrs. post-injection in 
wild type (B) and Polg (F), 48 hrs post-injection in wild type (C) and Polg (G) and 96 hrs post-
injection in wild type (D) and Polg (H). Nuclei staining – blue and S-phase cells – yellow 
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Measurements of Small Intestine Dimensions. Histological sections of the small intestine 
were examined to evaluate differences in gross morphology between wild type and PolgD257A 
mice. Villi length was comparable in the small intestine of PolgD257A mice compared to wild 
type mice (Fig. 3.5A). Villi width (Fig. 3.5B), crypt length (Fig. 3.5C), and crypt width (Fig. 
3.5D) were all significantly larger in PolgD257A mice compared to wild type mice. Thickness 
of the smooth muscle, measured at 50 random locations from the proximal to distal end of the 
small intestine, was significantly smaller in Polg D257A mice compared to wild type mice 
(Fig. 3.5E). The small intestine was slightly longer in PolgD257A mice compared to wild type 
mice (Fig. 3.5F), however the difference was not significant. These data show that the 
PolgD257A mutation affects the gross morphology of the small intestines and mimics changes 
in dimension found in the aging human small intestine. 
Alteration of Cell Cycle in Intestinal Crypts. Epithelial cells in the crypt region of both 
PolgD257A and wild type mice were labeled with a proliferation marker (KI67 – red) and cell 
cycle markers for S phase (EdU - green), G1 phase (MCM2 - blue), and M phase (pH3 - 
white). The numbers of proliferating cells detected by KI67 were similar in wild type (Fig. 
3.6A) and PolgD257A (Fig. 3.6G) crypts. As previously shown and reconfirmed here by EdU 
labeling, there are 2.5 times more crypt transit amplifying cells (progenitor cells) in S-phase 
(DNA synthesis) of wild type mice (Fig. 3.6B) than in PolgD257A mice (Fig. 3.6H). As 
measured by Anti-MCM2 staining, there are slightly fewer crypt epithelial cells in G1 phase 
(growth arrest prior to DNA synthesis) of wild type (Fig. 3.6C) than in PolgD257A (Fig. 3.6I) 
mice however the difference is not significant. There are significantly fewer crypt epithelial 
cells in late G2 (growth arrest prior to mitosis) and M-phase (Mitosis) of wild type mice (Fig. 
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Figure 3.5: Measurements of intestinal morphology. Approximately 25 villi and 25 crypts 
were measured per animal. A comparison of villus length (A) and width (B), crypt length (C) 
and width (D), smooth muscle thickness (E), and small intestine length (F) between wild type 
and Polg mice. All data are represented as Mean ± SEM. *** P < 0.001 between WT (n ≥ 4) and 
Polg (n ≥ 4) by Student’s t-test. 
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Figure 3.6: Cell cycle changes in PolgD257A crypt cells. Cell proliferation by KI67 (red) 
staining is equivalent in wild type (A) and Polg (G) crypts. S-phase labeling by EdU (green) is 
significantly higher (P < 0.001) in wild type (B) than in Polg (H). G1-phase labeling by MCM2 
(blue) are slightly lower (P = 0.057) in wild type (C) than in Polg (I). M-phase labeling by pH3 
(white) are lower (P < 0.01) in wild type (D) than in Polg (J). (E) Merge of A-D for wild type 
crypt and (K) merge of G-J for Polg crypt. The percentages of cells in each phase of the cell 
cycle were determined in wild type (F) and Polg (L) crypts. At least 50 crypts from 2 mice were 
used to generate percentage of cells in each phase. “Other” represents cells either in G2 or 
apoptosis. All statistics calculated based on Student’s t-test. 
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3.6D) than in PolgD257A mice (Fig. 3.6J) as measured by anti-pH3 staining. The percentage 
of cells in S-phase is significantly higher in wild type mice (Fig. 3.6F) than in PolgD257A 
mice (Fig. 3.6L). The decrease in S-phase cells in PolgD257A mice corresponds to a 
significant increase in M-phase cells suggesting that these cells are stalling in M-phase. There 
was a modest increase in the number of cells in both G1-phase (P = 0.057) and G2-phase (P = 
0.077) in PolgD257A mice compared to wild type mice. I conclude that the PolgD257A 
mutation does not change the number of proliferating cells in the crypt region. However, the 
PolgD257A mutation not only disrupts the synchronization of the cell cycle in the proliferating 
cells by decreasing cells in S-phase but also increases the percentage of cells in other phases of 
the cell cycle, suggesting a slowing of the cell cycle. 
Culturing of Isolated Crypts. Crypts were isolated from small intestines of 3-month-old 
PolgD257A and wild type mice to assess their ability to grow in culture. When in culture, 
isolated crypts lose the transit amplifying cells, and form a ball of cells that consist of the stem 
cells and paneth cells. The paneth cells provide many of the growth factors required by the 
stem cells, allowing effective growth of the stem cell population in vitro (21). During the first 
four days in culture, both wild type and PolgD257A populations of cells appeared to multiple 
at a similar rate and maintained a similar size (Fig. 3.7A). However by 8 days, the wild type 
cryptoid cultures (Fig. 3.7B) began to multiple at a faster rate and became larger than the 
PolgD257A cryptoids (Fig. 3.7C). Fourteen days after plating, the size of the wild type 
cryptoids (Fig. 3.7D) significantly increased and began to show multiple buddings (formation 
of new stem cells formed by symmetric cell division), while budding of the PolgD257A 
cryptoids were rarely found (Fig. 3.7E). Twenty days after plating, the wild type cryptoids (Fig 
3.7F) continued to increase in size and extent of budding while growth was arrested in the 
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PolgD257A cryptoids (Fig. 3.7G). After 20 days in culture, 7 of the 9 independent wild type 
crypts monitored continued to grow. In contrast, only 3 of the 13 independent PolgD257A 
crypts monitored continued to grow to limited degrees. Similar results were seen in crypts 
isolated from 7-month-old wild type and PolgD257A mice in culture (Data not shown). Thus, 
the in vitro culturing of intestinal crypts demonstrates that intestinal stem cells of the 
PolgD257A mice have a dramatic decrease in the ability to proliferate compared to those of 
wild type mice. I conclude that the PolgD257A mutation specific decrease in cell proliferation 
originates from the decreased growth potential of stem cells in the crypts. 
ATP Content in Isolated Intestinal Epithelial Cells. Epithelial cells were isolated from 3-
month-old PolgD257A and wild type mice. Sorting for CD44+, CD31- and CD45- yielded the 
stem and progenitor cells while sorting for CD44-, CD31- and CD45- yielded the terminally 
differentiated epithelial cells. In the stem and progenitor population of cells isolated from the 
crypt region, the content of ATP in PolgD257A (18.9 ± 0.3 fM ATP/cell) and wild type (19.5 ± 
0.6 fM ATP/cell) cells were similar (Fig. 3.8). In the terminally differentiated epithelial cells 
isolated from the villus region, the content of ATP in PolgD257A (6.2 ± 0.2 fM ATP/cell) cells 
were increased compared to wild type (5.4 ± 0.1 fM ATP/cell) cells (Fig. 3.8). This data 
suggests that the PolgD257A mutation does not affect the content of ATP of the intestinal stem 
and progenitor epithelial cells, but production of ATP in terminally differentiated cells are 
higher in PolgD257A mice than in wild type mice. 
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Figure 3.7: PolgD257A mutation impairs the culturing of isolated crypts. (A) Area of cell 
mass was determined on marked crypt cultures at days 1, 2, 4, 8, 14, and 20 after plating. Wild 
type cultures () grew at an exponential rate starting at day 4 in culture while Polg cultures (¾) 
only moderately increased in area through day 20. Wild type cultures at Days 8, 14, and 20 (B, 
D, F, respectively) have increased cellular mass with significant budding occurring at Days 14 
and 20. Polg cultures at Days 8, 14, and 20 (C, E, G, respectively) have reduced cellular mass 
with very few buds developing. All data are represented as Mean ± SEM. *** P < 0.001 
between WT (n =9) and Polg (n = 13) by Student’s t-test. 
 
Day 8 
Day 14 
Day 20 
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Figure 3.8: ATP content in isolated intestinal epithelial cells. Intestinal 
epithelial cells were isolated from wild type (n=2) and PolgD257A (n=2) 
mice. Single cell suspension was sorted for CD44. Positive CD44 cells 
contain stem and progenitor cells while negative CD44 cells contain 
terminally differentiated cells. All data are represented as Mean ± SEM. ** 
P < 0.01 between WT and Polg by Student’s t-test. 
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3.5 Discussion 
Mice homozygous for the PolgD257A mutation have been described as a model for 
premature aging with reduced lifespan and characteristics associated with human aging such as 
thinning of skin, graying and loss of hair, and kyphosis (17, 18). I characterized the small 
intestines of PolgD257A mice to determine if the intestines undergo a similar aging process as 
seen in humans. I confirmed that PolgD257A mice have increased apoptosis in the epithelial 
cells lining the villi and at the tip of the villi, but I find apoptosis was also significantly 
increased in the crypts. The increase in apoptotic cells in the crypt has not been described in 
humans, but may exist in the aging small intestine. In support of the increased apoptosis in the 
crypts, I find that the PolgD257A mutation causes a decrease in S-phase labeling in the transit 
amplifying cells and significantly reduced epithelial cell migration along the crypt-villus axis. I 
also find that the premature aging of the small intestine caused by the PolgD257A mutation are 
characterized by increased dimensions of both villi and crypt compartments. The number of 
proliferating cells in the small intestine of PolgD257A and wild type mice were similar. 
Despite these similarities, the number of cells in S-phase was significantly reduced and 
significantly more cells were in G1, M, or G2 phases of the cell cycle. Furthermore, isolated 
crypts in vitro revealed a proliferation defect that is linked to the stem cell population found in 
the crypts.  
It has been well documented that human small intestine undergoes an increase in villi 
and crypt dimensions with age (3, 4). Previous studies in aged mice and rats have provided 
further confirmation that aging leads to increased dimensions of villi and crypts (5, 6). Our 
observations that the histological changes of the villi and crypts occurs in mice at 7 months of 
age supports the premature aging of the small intestine initiated by the PolgD257A mutation. 
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The PolgD257A mutation was also shown to dramatically alter the histology of the small 
intestine at 10 months of age, with significant fusion and branching of the villi (17). The 
exaggerated branching seen in old PolgD257A small intestine villi may be unique to this aging 
model, since it has not been described in aged humans or rodents. While the branching of the 
villi was not a prominent feature in our 7-month-old PolgD257A mice, the histological changes 
such as increased height and width of the villi and crypt compartments in the premature aging 
PolgD257A small intestine closely mimic the aging induced changes seen in the human small 
intestine.  
Apoptosis is found at the tips of the villi in the small intestine, and is a normal event 
due to the high rate (3.3 days) of epithelial cell turnover (22, 23). The novel finding that 
PolgD257A mice have increased apoptosis in the crypt region suggests that these cells are 
undergoing a damage response induced by the increased mtDNA mutations produced by the 
PolgD257A mutation. The crypt region houses both stem and progenitor cells which are 
required to replenish epithelial cells lost during apoptosis. Under normal circumstances, there 
is a low level of spontaneous apoptosis in the crypt region that is thought to maintain the stem 
cell population by removing excess or damaged stem cells (24). Furthermore, damaging insults 
such as irradiation causes a significant increase in apoptosis particularly in the stem cell 
population in the crypt region (24). However, there are no reports of increased apoptosis in the 
transit amplifying cells (progenitors) of the crypt in aging humans and rodents. This suggests 
that stem and progenitor cells in the crypt are particularly susceptible to mitochondrial DNA 
damage triggered by the PolgD257A mutation, and prompt the need of further studies of 
apoptosis in the crypt in aging humans and rodents. 
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In conjunction with the increase in apoptosis, the PolgD257A small intestine was found 
to have a decreased number of S-phase cells. However, staining with KI67 (a marker of cell 
proliferation in all phases of the cell cycle) was similar in both PolgD257A and wild type mice. 
This observation indicates that the number of cells in a proliferating state was not affected by 
the PolgD257A mutation, yet the decrease S-phase labeling suggests that the PolgD257A 
mutation affects the cell cycle of these rapidly dividing transit-amplifying cells. Mitochondria 
have been shown to have an instrumental role in apoptosis (25-28), however the same can be 
said about cell division. Inhibition of mitochondrial protein synthesis leading to G1 arrest 
attenuates DNA replication (29, 30), whereas increasing mitochondrial DNA increases the 
transition from G1 to S and G2 to M thereby accelerating the progression through the cell cycle 
in yeast (31). Hence, mitochondria are critical to DNA replication. During Gap1 (G1) phase, all 
proteins required during DNA replication are synthesized. DNA synthesis occurs during the S-
phase of the cell cycle and requires pools of ATP for incorporation into DNA and energy for 
the cellular processes of DNA replication. After the completion of S-phase, the cell enters 
Gap2 (G2) phase where ATP is synthesized for mitosis (32). Cells exit G2 and enter Mitosis 
(M) phase during which the physical separation of chromosomes occurs through ATP mediated 
movement of kinesin down the microtubule and cell division takes place (33). Hence, ATP 
produced by the mitochondria is an essential requirement to drive the cell cycle. Analysis of 
markers for cell cycle, MCM2 for G1, pH3 for M, and EdU for S confirmed a shift in the 
percentage of cells in each phase of the cell cycle in the PolgD257A mice. PolgD257A mice 
had significantly more cells in phases G1, M and other (possibly G2) compared to wild type 
mice. I examined whether cells contain ATP at a reduced rate in PolgD257A mutants. 
However, no significant difference in ATP levels were seen in the isolated intestinal stem and 
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progenitor cells of PolgD257A and wild type mice. It is possible that this pool of cells contains 
a majority of cells undergoing typical cell cycling and a smaller population cells undergoing 
atypical cell cycling, which could explain the similar ATP levels. Collectively, the data 
suggests the PolgD257A mutation is consistent with mitochondrial dysfunction in some of the 
progenitor cells likely causing a decrease in ATP levels in just this subset of cells. A depletion 
of ATP in a subset of the progenitor cells would explain the slower cell cycle in the 
PolgD257A mutants and possible stalling at multiple stages during the cell cycle. However, 
further investigation into the subset of poorly dividing cells is necessary to determine the extent 
of stalling in the PolgD257A mutants. 
Two separate experiments showed that the migrations of epithelial cells from the crypt 
to the tip of the villi are severe in the mice with the PolgD257A mutation. The slower 
migration of PolgD257A epithelial cells is likely the result of two important contributions: (i) 
increased apoptosis in the crypts and (ii) the disruption of the cell cycle. The increase in 
apoptosis occurred mainly in the transit amplifying (TA) cells of the crypt. The sole function of 
TA cells are to increase the total number of cells for differentiation to enterocytes, goblet, 
enteroendocrine, and paneth cells, and to replenish lost or damaged epithelial cells. The 
actively dividing TA cells are essential in supporting cell migration by providing the push 
necessary to replenish the epithelial cells along the villi. The reduction in the actively dividing 
TA cells due to apoptosis contributes to a slower cell migration, reduced shedding of epithelial 
cells, and a prolonged presence of the epithelial cells in the villi. Prolonging the time the 
epithelial cells are in the villi may hamper epithelial cell function, yet this remains to be 
determined. Secondly, the observation that there are more cells in the stages other than S-phase 
of the cell cycle suggests that the cycling time of the cells in this region is longer than normal, 
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which contributes to the slower migration seen in the PolgD257A intestines compared to wild 
type intestines. Interestingly, these patterns were observed in PolgD257A mice at both 3 and 7 
months of age, suggesting that the PolgD257A mutation itself have a large impact on the small 
intestine regardless of age. 
In addition to TA cells, the crypt compartment contains intestinal stem cells, and I 
cannot eliminate the possibility that the PolgD257A mutation has a detrimental effect on the 
stem cell population. The isolation and culturing of crypts allows for the evaluation of the 
intestinal stem cell population in vitro since after plating the TA cells die and the only cells that 
remain are stem cells and paneth cells. In vitro the paneth cells provide the necessary factors 
required by the stem cells for maintenance and growth. In this in vitro system, the stem cells 
are capable of both symmetric and asymmetric division (20, 21, 34). Asymmetric division 
leads to progenitor cells while symmetric division leads to new stem cells that form a bud off 
the mass of growing cells. The observation of slower cell migration and increased apoptosis in 
the crypt region is supported by our results of a marked decrease in stem cell proliferation in 
PolgD257A mice compared to wild type mice. These results confirm that dysfunction at the 
stem cell level is a contributing factor involved in passing deleterious mutations on to 
progenitor cells leading to progenitor cell apoptosis and the decreased cell migration found in 
the PolgD257A small intestine. 
In conclusion, the PolgD257A mutation causes changes in the morphology of the small 
intestine similar to the age-associated changes in small intestine morphology of aging humans 
and mice. The changes in morphology are the result of increased apoptosis and a slower cell 
cycle in the proliferating progenitor and stem cells located in the crypts of Lieberkuhn. 
Histologically, the premature aging in the small intestines of the PolgD257A mice closely 
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mimics aging of the small intestine in humans, rats, and mice. However, the PolgD257A 
mutation appears to cause significantly more damage in the stem and progenitor cells located in 
the crypts. Whether this increase in damage is associated with intestinal dysfunction or found 
in aging humans remains to be determined. 
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C h a p t e r  4  
A MITOCHONDRIAL DNA POLYMERASE EDITING MUTATION PREVENTS DIET 
INDUCED OBESITY 
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4.1 Abstract 
Nutrient mal-absorption by the small intestine is prevalent problem in the elderly. 
Aging is thought to be the main contributing factor leading to the apparent mal-absorption yet 
the exact mechanism behind the dysfunction of the small intestine is not known. With the 
objective to determine if premature aging due to increased mitochondrial DNA mutations cause 
a mal-absorption phenotype, I examined mice homozygous for the PolgD257A mutation, 
which causes increased mitochondrial DNA mutations, for evidence of mal-absorption. 
PolgD257A mutant and wild type mice were administered a normal rodent chow (NC) or a 
high fat-high carbohydrate western-type diet (HFW). The PolgD257A mice on NC were 
indistinguishable from wild type mice on NC with regards to body weight, plasma 
measurements, and Respiratory exchange ration (RER). However on HFW, RER was increased 
in wild type mice while PolgD257A mice showed a slight increase. These mice also show 
increased excretion of fat in the feces and reduced fat absorption compared to wild type HFW 
mice. Triglyceride absorption was reduced in HFW mice compared to NC mice in both 
genotypes but mutant HFW mice show significantly lower triglyceride absorption. In the villi 
and crypt compartments, apoptosis was increased and proliferation was decreased in 
PolgD257A mice compared to wild type mice regardless of the diet. The only mitochondrial 
defect seen was a decrease in State III (ADP stimulated) respiration in PolgD257A HFW mice 
compared to wild type HFW mice. PolgD257A mice on HFW did not gain weight compared to 
wild type mice on HFW. Insulin resistance was observed in wild type HFW mice, but not in 
PolgD257A HFW mice. Together, these results show, under conditions of high dietary lipid 
load, that a mutant Polg protein results in an impaired ability to absorb lipid that is likely 
triggered by the increase in apoptosis and decrease in proliferation seen in the small intestines. 
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4.2 Introduction 
Intestinal dysfunction leading to mal absorption is common in the elderly (1, 2).  The 
exact mechanism behind the dysfunction of the small intestine is not known, but aging is 
thought to be the main contributing factor leading to the apparent mal-absorption. In humans, a 
compensatory increase in cell proliferation in the small intestines has been observed in the 
aging population correlating with increased size of the small intestine villi and crypt 
compartments (3, 4). Furthermore, aging in humans causes increased proliferation and 
apoptosis in enterocytes (5). Similarily, in aging rodents, increases in length and width of villi 
and crypt dimensions have been reported (6, 7). Additionally, cell proliferation in the small 
intestines of rats increases with age (8, 9), and while apoptosis is high in young rats, it 
decreases to low levels with age (9). However, there have been no comprehensive studies 
demonstrating how these changes in morphology and proliferation affect function. 
An instrumental role which mitochondrial DNA mutations play in the aging process is 
highlighted by the increase in the number of mutations found in aging individuals (10-14). 
Mitochondria are essential organelles responsible for generating energy in the form adenosine 
triphosphate (ATP) that is necessary for maintaining cellular function. Most efficient synthesis 
of ATP is the electron transport chain within the matrix of the mitochondria, coupled with 
oxidation of the reduced hydrogen carriers, NADH+H+ and FADH2, supplied by the 
tricarboxylic acid (TCA) cycle. During periods of high-energy demand, the number of 
mitochondria in the cell increases by fission in order to meet the energy demands (15, 16). 
Accumulations of mtDNA mutations and/or deletions, causes mitochondria dysfunction and 
leads to multiple disorders and that mainly affect metabolically active cell populations (17-23). 
Maintenance of the mitochondrial genome, both replication and repair, is carried out by the 
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nuclear gene, DNA polymerase gamma (Polg). Polg is essential for life as evidenced by the 
embryonic lethality of knock-out mice (24). D257A in exonuclease domain II disrupts the 
proofreading function of Polg, and causes an increase in mitochondrial DNA mutations. Mice 
homozygous for the PolgD257A mutation exhibit phenotypes consistent with premature aging 
(25, 26). Consequently, the PolgD257A mice provide a genetic means to study the effects of 
increased mitochondrial DNA mutations in the small intestine. 
Previous studies have shown that the small intestine has increased mitochondrial DNA 
mutations leading to increased apoptosis (25, 26). However, it is not known whether increases 
in apoptosis will affect intestinal absorption. I have shown in Chapter 3 that the PolgD257A 
mutation alters the cell cycle of the progenitor (transit amplifying) cells located in the crypts of 
Lieberkühn. I observed a reduced migration of epithelial cells along the crypt-villus axis which 
suggests that the PolgD257A mutation causes a slower than normal cell cycling. I have also 
shown that the increased apoptosis is not confined to the columnar epithelial cells of the villus, 
but also occurs in the stem and progenitor cells found in the crypts. Whether alterations to cell 
cycle and apoptosis in PolgD257A mice affects absorption by the small intestine remains a 
mystery.  
The goal of the experiments described in this chapter is to elucidate the effect of 
increasing mtDNA mutations in the small intestine on nutritional absorption, and on obesity 
and type 2 diabetes. I used the prematurely aging PolgD257A mice as a genetic tool to answer 
this question, and determine the role of mitochondrial DNA mutations in the functionality of 
the small intestine. I found that the PolgD257A mice on a normal rodent chow (NC) are not 
affected by the changes in cell cycle and apoptosis in the small intestine. However, PolgD257A 
mice on a high fat-high carbohydrate western-type diet (HFW) are protected against diet-
  106 
induced obesity and insulin resistance. I demonstrate that the changes in apoptosis and cell 
cycle in the small intestine of PolgD257A mice impairs the ability to absorb dietary lipids 
preventing the accumulation of fat without disturbing nutritional balance. 
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4.3 Methods 
Mice. The experimental animals were males homozygous for the PolgD257A mutation (Polg) 
from crosses between heterozygotes that have been extensively backcrossed onto a C57BL/6 
background. Controls were male littermates that are wild type at the Polg locus. Mice were fed 
ad libitum either NC [5.3% (w/w) fat and 0.019% (w/w) cholesterol, Prolab Isopro RMH 3000, 
ref 5P76; Agway Inc., Syracuse, NY] or HFW [21% (w/w) fat and 0.2% (w/w) cholesterol, 
TD88137; Teklad, Madison, WI] for 14 weeks.  The diet was administered starting at 4 months 
of age and continued throughout the course of the experiment.  
Plasma Analyses. Animals were fasted in the morning, 4 hrs prior to the collection of blood. 
Plasma glucose, 3-hydroxybutyrate (3-HB), and cholesterol were measured using colorimetric 
kits (#439-90901, #417-73501/601, and #439-17501, respectively, Wako Chemical Co., 
Richmond, VA). Plasma triglyceride was measured using a colorimetric kit (#2150, Stanbio 
Laboratory, Boerne, TX). Plasma insulin, leptin, and 25(OH)-Vitamin D were measured using 
ELISA kits (#90080 and #90030, Crystal Chem, Inc., Downers Grove, IL and #K2109, 
ALPCO Immunoassays, Salem, NH). Liver and plasma vitamin E were measured as previously 
described (27). 
Glucose and Insulin Tolerance Tests. For oral glucose tolerance tests (GTT), male mice of 
each genotype were fasted for 4 hrs prior to oral gavage of glucose (2g/kg BW).  Plasma was 
collected for glucose measurement 0, 15, 30, 60, or 120 minutes after gavage. For insulin 
tolerance tests (ITT), male mice of each genotype were fasted for 4 hrs prior to intraperitoneal 
injection of insulin (0.25U/kg BW).  Plasma was collected for glucose measurement 0, 15, 30, 
60, or 120 minutes after injection.  
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Measurement of Metabolic Parameters and Energy Expenditure. Mice were housed in 
metabolic cages for 48 hrs.  Mice were allowed to acclimate to the new environment for 24 hrs 
before data and sample collection.  Starting the second 24 hrs, body weight, food intake, water 
intake, and urine output was measured.  Urine and feces samples were collected over 24 hrs. 
For energy expenditure, indirect calorimetry and physical activity were measured using the 
Labmaster system (TSE Systems GmbH, Bad Homburg, Germany) as previously described 
(28, 29). Briefly, 3-month-old and 7-month-old mice were individually housed in a laboratory 
animal monitoring system that allows the continuous measurement of these parameters. Mice 
were monitored for 96 hrs with the first 24 hrs discarded to allow for acclimation to the cages. 
During the first 48 hrs, animals were fed NC. After 48 hrs, the diet was switched to HFW and 
monitored was continued for an additional 48 hrs. The final 24 hrs on either NC or HFW were 
used for all comparisons. 
Acid Steatocrit and Fecal Lipase. Acid steatocrit was measured as described previously (30) 
with minor modification. In short, 0.02 g of powdered specimen was mixed in 200 µl of 1 N 
perchloric acid. One drop of 0.5% Oil Red O was added and mixed. Specimens were placed in 
non-heparinized capillary tubes and spun. Steatocrit and daily fat absorption were calculated as 
previously described (31, 32). For lipase activity in the feces, 0.05 g of powdered specimen 
was mixed with 200 µL phosphate buffered saline (PBS).  Specimens were centrifuged and 
supernatant was transferred to a clean tube.  The supernatant was assayed for enzymes using an 
Automatic Chemical Analyzer (Johnson & Johnson’s VT250). 
Isolation of Small Intestines. Anesthetized animals were dissected and the small intestines 
exposed.  The small intestine was removed from the stomach to the cecum of the large 
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intestine. Isolated intestines were placed in ice cold PBS, and subsequently flushed with 10mls 
of ice cold PBS.  The intestines were split into two sections, duodenum to jejunum and jejunum 
to ileum.  Each section was placed into 4% PFA at 4°C for at least 24 hrs.  Intestines were then 
cut length wise and rolled for sectioning. Apoptosis was evaluated using a commercially 
available kit (ApopTag S7110; Chemicon Int.). Cells in S-Phase were determined as previously 
described (33) using a commercially available kit (Click-iT EdU C10084, Molecular Probes, 
Inc., Eugene, OR). 
Immunostaining. Small intestine was resected, flushed of fecal contents with ice cold PBS, 
cut open along the longitudinal axis, and fixed in 4% PFA for 16 hrs at 4 °C. The sections 
remained hydrated for the remainder of the immunostaining procedure.  Prior to 
immunostaining, the sections were blocked with 5% Normal Donkey Serum in PBS/0.1% 
TritonX (blocking buffer).  The primary antibody was diluted in blocking buffer. For lymphatic 
staining, sections were stained with LYVE-1 (1:200; #70R-LR005, Fitzgerald), and incubated 
with tissue at 4°C for 16 hrs. The tissues were then washed three times with PBS for 5 minutes. 
Cy2 conjugated secondary antibodies (#715-225-150, Jackson Immunoresearch Laboratories) 
were diluted in blocking buffer at 1:200, and applied to tissue sections for 45 minutes at 21°C. 
The tissues were then washed three times with PBS for 3 minutes each. For nuclear staining, 
DAPI was added to Flouromount-G (#0100-01, SouthernBiotech) and mounted with a cover 
slip. 
Histology. Tissues were fixed in 4% PFA. Paraffin sections of 5 µm were stained with 
Hematoxylin and Eosin, Periodic acid-Schiff, or Masson’s Trichrome. For transmission 
electron microscopy (JOEL USA, Inc.), small tissue fragments were post-fixed in 2% osmium 
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tetroxide and one-micron thick sections were stained with uranyl acetate followed by lead 
citrate. 
Gene Expression. Total RNA was purified from hypothalamus and pancreas using Trizol 
(#15596-026 Invitrogen, Carlsbad, CA) as previously described (34). Total RNA from other 
tissues was purified using an Automated Nucleic Acid Workstation ABI 6700. Real-time PCR 
was performed in an ABI PRISM 7700 Sequence Detector (Applied Biosystems, Foster City, 
CA). β-Actin mRNA was used for normalization.  
Enterokinase. Enterokinase activity was determined as previously described (35). Briefly, 
isolated small intestine from duodenum was homogenized on ice for 2 minutes in extraction 
buffer: 20 mM Tris-HCl, 150 mM NaCl, 1% Triton X-100. 20 µL of homogenized tissue was 
added to 80 µL of reaction buffer: 125 nM trypsinogen, 0.07 M sodium succinate, and 
incubated 30 minutes at room temperature. The reaction was stopped with 2 µL 2 M HCl. The 
amount of trypsin generated from trypsinogen during the reaction is correlated to the amount of 
enterokinase present in the homogenized tissue. The amount of trypsin was determined by 
addition of 100 µL of detection buffer: 40 mM Tris-HCl (pH-8.0), 300 mM NaCl, 10 mM 
CaCl2, 200 µM chromogenic substrate S-2765 (Chromogenix). An increase in absorbance at 
405 nm was monitored immediately following the addition of the detection buffer. 
TG secretion, TG absorption, and Vitamin E absorption. The rate of triglyceride secretion 
from the liver was determined as previously described by Johnson et al (36). At 7 months of 
age, male mice of each genotype fed either NC or HFW were fasted for 4 hrs prior to injection 
of Tyloxapol (Triton WR-1339; Sigma Chemical Co., St. Louis, Missouri, USA) via retro-
orbital injection at a dose of 0.7 mg/g body weight.  Plasma was collected for triglyceride 
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measurement at time points of 0, 15, and 30 minutes after injection.  Immediately following the 
30 minutes plasma collection, the animals were challenged with 250 µL/30 g body weight of 
Olive oil with (1 mg/kg) deutrated vitamin E.  Plasma was collected for triglyceride 
measurement at 60, 120, and 180 minutes after oral gavage. Pooled plasma samples were 
measured for Vitamin E as previously described (37). 
Oxygen Consumption in Small Intestine Homogenates. Briefly, small intestines were 
removed and flushed with ice cold PBS.  A ~200 mg section of intestine was gently 
homogenized in SET buffer (250 mM Sucrose, 1 mM EDTA, 10 mM Tris-HCl, 2 mM ATP 
pH 7.4).  Total protein was measured using a BCA protein assay kit (cat. 23227, Thermo Fisher 
Scientific, Inc), and samples were normalized to total protein. Intestinal homogenate was 
placed into a BD Oxygen Biosensor System and O2 was measured.  A 2X Reaction buffer, 
containing 125 mM Sucrose, 25 mM K2HPO4, 200 mM KCl, 2.5 mM MgCl2, 2.5 mM L-
Carnitine, 0.25 mM Malic Acid, 20 mM Tris-HCl, 2.5 mM DTT, 0.25 mM NAD+, 4.0 mM 
ATP, and 0.125 mM CoA, was prepared and added to the plates with homogenates.  
Fluorescence was measured using a FLUOstar microplate fluorometer (BMG LabTech) with 
excitation at 485 nm and emission at 612 nm every 3 minutes over a period of 120 minutes.   
Isolation and Assessment of Mitochondria. Mitochondria were isolated from livers as 
previously described (38). Isolated liver mitochondria (5 µg protein) in buffer (70 mM sucrose, 
220 mM mannitol, 10 mM KH2PO4, 2 mM MgCl2, 2 mM HEPES, 1 mM EDTA, 0.1% BSA, 5 
mM succinate, and 2 µM rotenone) were loaded onto XF24 plates. The rate of O2 consumption 
was measured according to the manufacturer's instructions with a Seahorse XF24 Analyzer 
(Seahorse Bioscience; North Billerica, MA) during the consecutive addition at 6 minute 
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intervals of 0.5 mM ADP, 2 µM oligomycin, 4 µM FCCP, and 2 µM antimycin A. For each 
experiment, mitochondria from one mouse was isolated, and assayed in triplicate. The 
experiment was repeated with another mouse and produced essentially the same results. 
Analysis of Mitochondrial DNA Copy Number and D17 Deletions. DNA was isolated from 
tissues and Real-time PCR amplification for the Cytochrome b gene was performed to assay 
mitochondrial DNA content using amplification of the Na-K-Cl cotransporter 2 gene (NKCC2) 
as an indicator of the content of nuclear DNA. A deletion of ~3.8 kb in relation to the D-loop 
of mtDNA was assayed using a primer probe set that recognizes the loss of the D-17 region in 
the mtDNA genome. The extent of D-17 deletions was expressed relative to the mtDNA gene 
coding for Cytochrome b in each animal.  
Data Analysis.  Values are reported as mean ± SEM.  Statistical analyses were conducted with 
JMP 6.0.2 software (SAS Institute, Cary, NC). P values less than 0.05 were considered 
significant.  
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4.4 Results 
PolgD257A mutation protects against obesity. Wild type and PolgD257A mice were 
followed monthly starting at one month of age. At four months of age, wild type and 
PolgD257A mice were either continued on NC or switched to HFW and followed for three 
additional months. While on NC, both wild type and PolgD257A mice gained equal body 
weight throughout the study. Wild type mice fed a HFW diet gained significantly more body 
weight compared to wild type mice fed a NC. Strikingly, PolgD257A mice fed a HFW diet did 
not gain additional body weight compared to wild type and PolgD257A mice fed a NC diet 
(Fig. 4.1A). Accumulation of fat in both inguinal and gondal fat pads contributed to the weight 
gain of wild type mice fed HFW diet. While on NC, Wild type and PolgD257A mice have 
similar gross inguinal and gonadal fat weight. Conversely, PolgD257A mice fed a HFW diet 
had similar inguinal and gonadal fat pads as wild type and PolgD257A mice fed a NC diet (Fig. 
4.1B, C). This data shows that PolgD257A mutant mice are refractory to weight gain on a 
HFW diet.  
Insulin resistance in PolgD257A mice. At 3 and 7 months of age, both WT and Polg mice 
were challenged with an oral gavage of glucose, and monitored for clearance of glucose. At 3 
months of age, WT and Polg mice on a NC diet respond similarly to a glucose challenge (Fig. 
4.2A). In addition, plasma insulin, in response to the increase in glucose, is stimulated to the 
same degree in both WT and Polg mice (Fig. 4.2B). At 7 months of age, WT and Polg mice on 
a NC diet also respond similarly to a glucose challenge (Fig. 4.2C), and plasma insulin is also 
stimulated to the same degree in both WT and Polg mice (Fig. 4.2D). WT mice on HFW diet 
for 3 months had a poor response to the glucose challenge, developed mild insulin resistance, 
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Figure 4.1: PolgD257A mice are protected from diet induced obesity. (A) Body 
weight prior to and after administering high fat diet. Gross weight of (B) inguinal and 
(C) gondal fat pads in WT and Polg mice administered either a normal or western diet. 
All data are represented as Mean ± SEM. *** P < 0.001 between WT NC (n = 9), Polg 
NC (n = 9), WT HFW (n = 12), and Polg HFW (n = 8) by Tukey-Kramer HSD.  
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Figure 4.2: Oral glucose tolerance test. (A) Percent change of plasma glucose in 3-month-old 
following an OGTT in WT NC (n = 24) compared to Polg NC (n = 12) (B) Plasma insulin levels prior 
to (0 min) and after (15 and 30 min) glucose challenge in 3-month-old WT NC compared to Polg NC. 
(C) Percent change of plasma glucose in 7-month-old following an OGTT in WT NC (n = 8) 
compared to Polg NC (n = 10) (D) Plasma insulin levels prior to (0 min) and after (15 and 30 min) 
glucose challenge in 7-month-old WT NC compared to Polg NC. (E) Percent change of plasma 
glucose in 7-month-old following an OGTT in WT HFW (n = 7) compared to Polg HFW (n = 8) (D) 
Plasma insulin levels prior to (0 min) and after (15 and 30 min) glucose challenge in 7-month-old WT 
HFW (n = 3) compared to Polg HFW (n = 3). All data are represented as Mean ± SEM. ** P < 0.01 by 
Student’s t-test. 
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and elevated plasma insulin levels (Fig. 4.2E, F). However after 3 months of HFW diet, Polg 
animals did not show a poor response to glucose challenge; rather, they responded similar to 
WT and Polg mice on NC diet, and did not develop insulin resistance (Fig. 4.2E, F). These 
results demonstrate that PolgD257A mice on HFW do not develop insulin resistance or glucose 
intolerance. 
Plasma measurements. Metabolic parameters were measured in wild type and Polg mutant 
mice prior to and after administering a HFW diet. A summary of all metabolic parameters 
measured throughout the course of this study is shown in Table 4.1. In 3 month old Polg and 
wild type mice, plasma glucose, plasma cholesterol, and plasma insulin remained the same. At 
3 months, Polg mice have lower plasma triglycerides, water consumption, and food 
consumption compared to wild type mice. By 7 months of age, Polg and WT mice fed a NC 
diet had similar plasma levels of cholesterol, glucose, insulin, leptin, 3-hydroxybutyrate, and 
triglycerides. Food consumption, water consumption, Vitamin D, and Vitamin E were the same 
in 7-month-old WT and Polg mice regardless of the diet. Plasma levels of 3-hydroxybutyrate, 
triglycerides, Vitamin D, and Vitamin E were similar in HFW diet fed WT and Polg mice. 
However, plasma leptin, insulin, and glucose were increased in WT HFW diet mice compared 
to Polg HFW diet mice. A dietary effect, HFW > NC, was observed by two-way ANOVA in 
plasma cholesterol (P < 0.001), plasma insulin (P < 0.001), plasma leptin (P < 0.001), plasma 
vitamin E (P < 0.05), food consumption (P < 0.01), and water consumption (P < 0.01). A 
genotype effect, WT > Polg, was observed by two-way ANOVA in plasma glucose (P < 0.01), 
plasma insulin (P < 0.001), plasma leptin (P < 0.001), and plasma 3- hydoxybutyrate (P < 
0.05). A diet- genotype interaction was observed in WT HFW diet mice by two-way ANOVA  
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in plasma insulin (P < 0.001) and plasma leptin (P < 0.01). Together these data show that WT 
mice administered HFW diet develop many of the metabolic changes seen in obesity such as 
plasma increases in insulin and leptin yet the PolgD257A mice given HFW diet do not respond 
in the same way and remain similar to NC administered mice. 
Increased daily fecal fat excretion. At 7 months of age, after receiving either NC or HFW 
diets, feces were collected from WT and Polg mice over a period of 24 hrs. Each sample was 
analyzed for fat content in feces by acid steatocrit and fecal lipase levels were measured. Daily 
fat excretion and percentage of fat absorbed were calculated based on food consumption, acid 
steatocrit, and total feces weight. No significant differences in these parameters were observed 
between WT and Polg mice fed NC.  Acid steatocrit was significantly higher in animals fed the 
HFW diet compared to animals consuming a NC diet (Diet effect, P < 0.001 by ANOVA). 
Acid steatocrit was significantly higher in Polg mice compared to WT mice (Genotype effect, 
P < 0.01 by ANOVA). A significant diet and genotype interaction (P < 0.02) reflects 
significantly higher acid steatocrit in Polg than in WT after HFW diet for 3 months (Fig. 4.3A). 
Similarly, the feces collected from HFW diet Polg mice contained elevated active lipase levels 
compared to HFW diet WT mice (Fig. 4.3B, P < 0.02 for a genotype effect and P < 0.04 for a 
diet-genotype interaction). Since dry weights of feces produced by mice administered HFW 
diet for 3 months were less than those produced by NC fed mice, daily fecal fat excretion of the 
WT mice fed HFW did not differ from those of the mice fed NC, suggesting that they are 
absorbing on average four times more fat. In contrast, daily fat excretion was significantly 
increased in HFW fed Polg mice (Fig. 4.3C). Daily fat absorption is significantly reduced in 
Polg HFW diet mice than in WT HFW diet mice (Fig. 4.3D, no effects or interactions by  
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Figure 4.3: Fecal steatocrit in PolgD257A mice. (A) Fecal steatocrit, (B) Fecal lipase, 
(C) Daily fat excretion, and (D) Daily fat absorption in 7-month-old WT NC (n = 7), 
Polg NC (n = 8), WT HFW (n = 11), and Polg HFW (n = 13). All data are represented 
as Mean ± SEM. *** P < 0.001, ** P < 0.01, and * P < 0.05 by Tukey-Kramer HSD.  
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ANOVA), although these mice still absorbed about 2.7 times more fat per day compared to NC 
fed mice. These data show that, under conditions of excessive dietary lipids, the PolgD257A 
mutation contributes to increased excretion and reduced absorption of lipid. Furthermore, the 
elevated lipase levels suggest that the components required for lipid absorption are available 
for processing dietary fat. 
PolgD257A mice on HFW diet have a reduced lipid absorption rate. Liver secretion of 
triglycerides was determined by injection of tyloxapol into both WT and Polg mice given either 
a NC or HFW diet. At 7 months of age, liver secretion was similar in Polg and WT on both 
diets (Fig. 4.4A). In NC mice, TG secretion from WT livers (5.5 ± 0.2 mg/dL/min) was slightly 
higher than TG secretion from the Polg livers (4.1 ± 0.5 mg/dL/min), diet significantly reduced 
TG secretion from the liver (P < 0.001), but TG secretion was similar in livers from WT (4.2 ± 
0.2 mg/dL/min) and Polg (3.9 ± 0.7 mg/dL/min) (Fig. 4.4B). Analyzing together by ANOVA, 
Polg mice secrete less TG than WT mice (genotype effect, P < 0.001).  
To determine the acute absorption capacity of the small intestine, WT and Polg mice 
were administered an oral gavage of olive oil to represent a bolus of dietary triglycerides. In 
mice fed NC for 3 months, both Polg and WT mice absorbed exogenously administered 
triglycerides at a similar rate (Fig. 4.4C). TG absorption by the small intestine of WT (24.4 ± 
1.6 mg/dL/min) mice was slightly higher than Polg (21.8 ± 1.6 mg/dL/min) TG absorption by 
the small intestines, but the difference was not significant. In contrast, TG absorption was 
reduced in both WT and Polg mice conditioned on HFW for 3 months (diet effect, P < 0.001 
by ANOVA). WT HFW mice experience a 51.2% reduction in the amount of triglycerides 
absorbed compared to WT NC mice whereas Polg HFW mice experience a 70.8% reduction in  
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Figure 4.4: Triglyceride secretion and absorption. Animals were injected with 
tyloxapol and triglyceride secretion form the liver determined by plasma collections at 
0, 15, and 30 minutes post tyloxapol injection. Plasma TG (A) and TG secretion (B) was 
the same in WT NC, Polg NC, WT HFW, and Polg HFW. At 30 minutes post tyloxapol, 
animals were administered a bolus of olive oil and plasma collected at 60, 120, and 180 
minutes post olive oil gavage. Plasma TG (C) and TG absorption (D) were similar in 
normal diet fed mice. High fat diet decreased TG absorption in both mice with Polg 
HFW being significantly lower than WT HFW. All data are represented as Mean ± 
SEM. * P < 0.05 by Tukey-Kramer HSD.  
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the amount of triglycerides absorbed by the small intestine compared to Polg NC mice. A 
comparison of animals in the HFW group shows that the Polg mice have a reduced triglyceride 
absorption (8.1 ± 0.7 mg/dL/min) that is 40.3% lower than the WT mice (12.2 ± 0.9 
mg/dL/min, P < 0.05). This data confirms that Polg mice have an impaired ability to absorb 
dietary lipids through the small intestine. 
Pancreatic gene expression of digestive enzymes.  Gene expression in the pancreas was 
determined to test whether the Polg mice have impaired production of the essential enzymes 
required during digestion. In mice given HFW for 3 months, gene expression of insulin is 
dramatically increased only in WT mice confirming an increase in insulin production seen in 
these mice (Table 4.2). Expression of genes related to digestion of fat and proteins, Pnlip, Clps, 
Prss1, and Ctrb1, in the pancreas was not affected by genotype and diet (Table 4.2). Pancreatic 
gene expression of Amy2 was higher in WT mice than in Polg mice (genotype effect, P < 0.05 
by ANOVA). These results confirm the pancreas is producing normal levels of the digestion 
enzymes: lipase, co-lipase, trypsinogen, and chymotrypsinogen. However, the PolgD257A 
mutation has a negative effect on the production of Amylase, for carbohydrate digestion. 
Enterokinase activity. Enterokinase, also known as enteropeptidase, is responsible for the 
cleavage and activation of trypsinogen to trypsin, and this activation step occurs in the 
duodenum in the small intestine (39). Relative enterokinase activity as determined by the 
conversion of trypsinogen to trypsin was the same in both Polg and WT mice given HFW diet 
for 3 months (Fig. 4.5). This result shows that the PolgD257A mutation does not disrupt the 
activity of enterokinase.
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Figure 4.5: Enterokinase. Relative activity 
of enterokinase in small intestine isolated 
from 7-month-old wild type and Polg mice 
administered high fat diet. All data are 
represented as Mean ± SEM. WT (n = 8) and 
Polg (n = 6) 
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Small intestine morphology. As described in Chapter 3, villi length is similar in WT (372 ± 
10 µm) and Polg (382 ± 11 µm) mice fed NC diet for 3 months. However, villi width increased 
in Polg NC diet (65 ± 1 µm) compared to WT NC diet (57 ± 1 µm, P < 0.001). In NC diet, 
Polg crypt length (97 ± 3 µm) and width (52 ± 1 µm) are markedly larger (P < 0.001) 
compared to WT crypt length (71 ± 1 µm) and width (41 ± 1 µm). In NC diet, smooth muscle 
thickness decreases in Polg mice (39 ± 2 µm) compared to WT mice (47 ± 2 µm, P < 0.01). 
HFW diet increases villi length (P < 0.001 by ANOVA) in both WT (434 ± 14 µm) and Polg 
(532 ± 12 µm) while Polg HFW diet mice have longer villi compared to WT HFW diet mice (P 
< 0.001). HFW diet increases villi width (P < 0.001 by ANOVA) in WT (62 ± 1 µm) and Polg 
(65 ± 2 µm) mice. HFW diet decreases crypt length (P < 0.001 by ANOVA) and width (P < 
0.001 by ANOVA) in both WT and Polg mice. In Polg HFW diet mice, crypt length (76 ± 2 
µm) and width (42 ± 1 µm) are markedly larger than WT HFW diet crypt length (59 ± 1 µm, P 
< 0.001) and width (34 ± 1 µm, P < 0.001). HFW diet increases smooth muscle thickness (P < 
0.001 by ANOVA) in WT (50 ± 1 µm) and Polg (43 ± 2 µm) mice. The thickness of the 
smooth muscle is markedly reduced in Polg HFW mice compared to WT HFW mice (P < 
0.01). Table 4.3 summarizes the differences found in intestinal morphology measurements. 
Overall, the Polg mutation contributes to morphology changes in the small intestine, but the 
changes are not exacerbated by the administration of HFW diet. 
The small intestine lacteals are important for delivering fat into the blood (40). 
Morphological changes such as dilation due to lacteal obstruction in the small intestine can 
impact the transport of fats into the body (41, 42). Intestinal lacteals, as assessed by Lyve-1 
staining, were not different in WT (Fig. 4.6A) and Polg (Fig. 4.6B) mice. Furthermore when 
mice were fed a HFW diet, intestinal lacteals did not change in size nor shape in WT (Fig.  
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Figure 4.6: Small intestine lacteals. Immunostaining of small intestines with Lyve-1 in 
(A) WT NC, (B) Polg NC, (C) WT HFW, and (D) Polg HFW shows no discernible 
differences in lymphatic structure regardless of diet and genotype. 
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4.6C) and Polg (Fig. 4.6D) mice. When combined, these data suggest that the small intestine 
undergoes age related changes in morphology caused by the PolgD257A mutation; however 
the morphology of the intestinal lacteals is not disturbed. 
Small intestine apoptosis and S-phase proliferation. As described in Chapter 3, WT mice 
have apoptosis that is confined to the tips of the villi (Fig. 4.7A, yellow arrows). The 
PolgD257A mutation increases apoptosis in the villi of the small intestines (Fig. 4.7B, small 
yellow arrows). HFW diet increases apoptosis (diet effect P < 0.001 by ANOVA) mainly at the 
tips of the villi in both WT (Fig. 4.7C) and Polg mice (Fig. 4.7D). In both diets, the 
PolgD257A mutation increases apoptosis in the villi as compared to WT mice (Fig. 4.7E, 
genotype effect P < 0.001 by ANOVA). The elevated levels of apoptosis in the villi caused by 
both PolgD257A mutation and HFW diet contribute to a diet-genotype interaction (P < 0.05 by 
ANOVA). 
HFW diet does not increase apoptosis in the crypt region in WT mice (Fig. 4.8C) 
compared to NC diet WT mice (Fig. 4.8A). As I have previously described in chapter 3, the 
PolgD257A mutation increases apoptosis in the crypts. Polg mice in both diets have increased 
apoptosis in the crypt compartment (Fig. 4.8B, D) compared to WT mice. There is a strong 
PolgD257A effect in the crypt region (P < 0.001 by ANOVA) as evident by the increase in 
apoptosis seen in both diets of Polg mice compared to WT mice (Fig. 4.8E). No diet effect and 
no interaction between diet and genotype in apoptosis of the crypt compartment were observed 
by ANOVA.  
As previously described in Chapter 3, the PolgD257A mutation decreases S-phase 
proliferation in the crypts. In both diets, the PolgD257A mutation decreases S-phase cell 
proliferation in Polg mice (Fig. 4.9B, D) compared to WT mice (Fig. 4.9A, C). HFW diet  
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Figure 4.7: Apoptosis in wild type and PolgD257A small intestines. (A) wild type small intestine 
with apoptosis located at tip of each villus with large yellow arrows indicating apoptotic cells. (B) 
Polg small intestines have similar levels of apoptosis at the tip of each villus indicated with large 
yellow arrows. Small yellow arrows indicate an increase in apoptotic cells in the columnar epithelial 
cells along the length of the villi. Apoptosis increases slightly with high fat diet in both (C) wild type 
small intestines and (D) Polg small intestines. (E) Quantification of apoptosis found in the villi. All 
data are represented as Mean ± SEM. ** P < 0.01 between WT (n = 11) and Polg (n ≥ 8) by Tukey-
Kramer HSD. Nuclei staining – blue and Apoptosis – green 
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Figure 4.8: Apoptosis of small intestine in the crypts of Lieberkuhn. (A) Apoptosis and S-phase 
proliferation in Wild type and PolgD257A crypts of Lieberkuhn.  Apoptosis is located in the region 
of the transit amplifying cells of wild type (A) and Polg (B) crypts in normal diet administered mice. 
Wild type crypts have few apoptotic cells in this region while Polg mice have numerous apoptotic 
cells. High fat diet does not change apoptosis in this region, however apoptosis in wild type (C) 
remains lower than Polg (D) mice administered high fat diet. Quantification of apoptotic cells per 
crypt (E) comparing wild type and Polg mice administered either normal or high fat diet. All data are 
represented as Mean ± SEM. *** P < 0.001 between WT (n ≥ 8) and Polg (n ≥ 8) by Tukey-Kramer 
HSD. Nuclei staining – blue and Apoptosis – green 
 
  131 
 
Figure 4.9: S-phase cell proliferation in the crypts of Lieberkuhn. EdU incorporation in S-phase 
cells in the transit amplifying region is found in the crypts of wild type (A) and Polg (B) mice 
administered normal diet. Wild type mice have numerous and robust staining of S-phase cells in this 
region while Polg mice have fewer and less intense staining of S-phase cells in this region. High fat 
diet reduces the intensity of s-phase labeled cells in wild type (C) and Polg (D) compared to normal 
diet mice. Polg staining is reduced compared to wild type mice regardless of diet. Quantification of 
S-phase proliferating cells per crypt (E) comparing wild type and Polg mice administered either 
normal or high fat diet. All data are represented as Mean ± SEM. *** P < 0.001 between WT (n ≥ 6) 
and Polg (n ≥ 6) by Tukey-Kramer HSD. Nuclei staining – blue and S-phase cells – yellow 
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significantly decreases S-phase cell proliferation in the crypt region as compared to NC diet 
(diet effect P < 0.05 by ANOVA). There is a strong PolgD257A effect in the crypt region as 
evident by the decrease in S-phase cell proliferation (Fig. 4.9E, P < 0.001 by ANOVA) 
compared to WT mice. No interaction between diet and genotype were observed by ANOVA. 
Together, these data suggest that the PolgD257A mutation markedly affects the small intestine 
by increasing apoptosis and decreasing S-phase cell proliferation; however, HFW diet does not 
affect these changes in PolgD257A mice. 
Small intestine gene expression.  Intestinal gene expression of transporters and co-
transporters were evaluated to determine if the PolgD257A mutation decreases mRNA levels 
thereby reducing the transport of compounds across the epithelial cell membranes. There were 
no differences seen in WT and Polg mice on either diet in the following transporter genes: 
SGLT (Solute carrier family 2 – sodium/glucose), Octn2 (Solute carrier family 22 – organic 
cation), Mct1 (Solute carrier family 16 – monocarboxylic acid), Nbc3 (Solute carrier family 4 – 
sodium bicarbonate), Hpt1 (Cadherin 17), Fabp1 (fatty acid binding protein 1), Fabp2 (fatty 
acid binding protein 2), Svct1 (Solute carrier family 23 member 1 – nucleobase), and NaDC-1 
(Solute carrier family 13 member 2 – sodium-dependent dicarboxylate). Glut2 (Solute carrier 
family 2 – facilitated glucose) and Sfxn1 (Sideroflexin 1 – iron) were significantly lower in 
Polg mice compared to WT mice (P < 0.01 by ANOVA), but not affected by diet. Pept1 
(Solute carrier family 15 – oligopeptide) was significantly lower in HFW diet mice compared 
to NC diet mice (P < 0.05 by ANOVA), but not affected by genotype. No differences were 
found in Na/K ATPase α1 and β1, both of which are required for the establishment of the 
Na+/K gradient used during co-transport of molecules. Table 4.4 summarizes the gene 
expression of the various small intestine transporters tested. These data demonstrate that gene 
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expression of most intestinal transporters remains unchanged in the presence of the PolgD257A 
mutation regardless of the diet administered. 
Assessment of mitochondria. Total DNA was isolated from tissues and real-time PCR 
amplification for the Cytochrome b gene was performed to assay mitochondrial DNA content 
using amplification of the Na-K-Cl cotransporter 2 gene (NKCC2) as an indicator of the 
content of nuclear DNA. No differences in mitochondria DNA content (Fig. 4.10A-D) were 
observed in the intestine, pancreas, kidney, or liver. A diet effect was seen in the content of 
mtDNA only in the liver where HFW diet significantly reduced the mtDNA content compared 
to NC diet (P < 0.05 by ANOVA). The D-17 deletion, a deletion of ~3.8kb in relation to the D-
loop, in the mtDNA genome was determined relative to the presence of the mitochondrial 
cytochrome b gene. No differences were found in the D17 deletions (Fig. 4.10E-H) within the 
small intestine, pancreas, or kidney. The deletion was increased in WT HFW livers but not in 
Polg HFW, confirming that HFW feeding stressed the WT livers but not so in the Polg livers. 
In homogenized tissue, oxygen consumption occurs by both mitochondrial and non-
mitochondrial origins with the majority of respiration occurring via mitochondria. Oxygen 
consumption in crude small intestine homogenates showed no difference between the two 
genotypes (Fig 4.11). Oxygen consumption by the crude small intestine homogenate was 
dramatically increased in mice fed a HFW diet compared to those fed NC diet, yet there were 
no differences between Polg and WT mice in either diet group.  
Due to the heterogeneous population of cells found in the small intestines and the 
multiple sources of respiration found in cells, isolated mitochondria from the liver was used to 
determine the functional characteristics of the mitochondria from WT and Polg mice. 
Mitochondria isolated from WT and Polg mice fed NC diet had a similar bioenergetics profile
  135 
 
 
Figure 4.10: Mitochondrial DNA in the small intestine (A, E), pancreas (B, F), kidney (C, G), 
and liver (D, H). DNA was isolated from tissues and Real-time PCR amplification for the 
Cytochrome b gene was performed to assay mitochondrial DNA content using amplification of the 
Na-K-Cl cotransporter 2 gene (NKCC2) as an indicator of the content of nuclear DNA. A deletion of 
~3.8kb in relation to the D-loop of mtDNA was assayed using a primer probe set that recognizes the 
loss of the D-17 region in the mtDNA genome (A, B, C, D) Mitochondrial DNA content relative to 
genomic DNA and (E, F, G, H) D17 deletions in the pancreas, kidney, and small intestine, 
respectively, of 7 month old wild type NC, Polg NC, wild type HFW, and Polg HFW. The extent of 
D-17 deletions was expressed relative to the mtDNA gene coding for Cytochrome b in each animal. 
All data are represented as Mean ± SEM. (n ≥ 8) Numbers in the bars indicate the number of 
animals. 
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Figure 4.11: Oxygen consumption by small intestine homogenates. High fat diet increases 
oxygen consumption in both wild type and PolgD257A small intestine homogenates compared to 
normal diet administered wild type and PolgD257A small intestine homogenates. No difference was 
observed between genotypes. All data are represented as Mean ± SEM in 7-month-old WT NC (n = 
6), Polg NC (n = 6), WT HFW (n = 4), and Polg HFW (n = 4). 
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Figure 4.12: Bioenergetics of isolated liver mitochondria. Bioenergetic profiles of isolated 
mitochondria from wild type and PolgD257A mice when administered normal diet (A) and high fat 
diet (B) measuring oxygen consumption during sequential injections of ADP (1), Oligomycin (2), 
FCCP (3), and Anti-mycin A (4). State II “basal” respiration (C), State III “ADP stimulated” 
respiration (D), State IV “ADP exhausted” respiration (E), State IVo “ATP inhibited” respiration 
(F), and State IIIu “uncoupled” respiration (G) in 7-month-old WT NC, Polg NC, WT HFW, and 
Polg HFW. All data are represented as Mean ± SEM. *** P < 0.001, ** P < 0.01, and * P < 0.05 by 
Tukey-Kramer HSD. 
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(Fig. 4.12A). HFW diet decreased the bioenergetics profile in both WT and Polg isolated 
mitochondria (Fig. 4.12B). Both WT and Polg mice fed HFW diet for three months had 
reduced respiration at State II (basal respiration), IVo (ATP synthesis blocked), and IIIu 
(coupling abolished) compared to NC diet mice (Fig. 4.12C, F, G). Isolated mitochondria from 
Polg mice fed a HFW diet have a lower State III respiration, reduced ability to convert ADP to 
ATP, after administering ADP than WT mice fed a HFW diet (Fig. 4.12D). Respiration at State 
IV was reduced in only Polg mice on HFW diet compared to Polg mice on NC diet (Fig. 
4.13E). Multifactorial ANOVA revealed dietary effects in State II, IV, IVo, and IIIu where NC 
diet values are significantly higher than HFW diet values. Multifactorial ANOVA also revealed 
a genotype effect in State III, IV, IVo, and IIIu where WT values are significantly higher than 
Polg values. No diet-genotype interaction was found by ANOVA in this study. Taken together, 
these data show that while mitochondria copy number and damage via DNA deletions are not 
increased in Polg mice, mitochondria function of Polg mice fed HFW diet is impaired at 
complex V, the mitochondrial encoded portion of ATP synthase that converts ADP to ATP. 
Oxygen consumption and basal metabolic rate. Both young (3-months) and old (7-months) 
WT and Polg mice were placed into Oxymax cages to determine metabolic activity while on 
NC and HFW diet. At 3 months of age, Respiratory Exchange Ratio (RER) in WT and Polg 
mice are similar when administered NC, but replacement with HFW causes RER in WT mice 
to dramatically increase to >1.0 while Polg mice show a blunted response compared to mice on 
NC diet (Fig. 4.13A). Similarly, at 7 months of age, RER in WT and Polg mice are similar 
when administered NC diet, but replacement with HFW causes RER in WT mice to 
dramatically increase to >1.0 while Polg mice show a blunted response compared to mice on 
NC diet (Fig. 4.13B). In both 3-month and 7-month mice, basal metabolic rate (Fig. 4.13C, F), 
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activity (Fig. 4.13D, G), and heat generation (Fig. 4.13E, H) were not different between WT 
and Polg mice administered either diet. In 3-month-olds, food consumption in WT mice after 
switch to HFW diet (4.8 ± 0.2 g/Day) was significantly higher than Polg mice after switching 
to HFW diet (3.6 ± 0.2 g/Day). In 7-month-olds, food consumption in WT mice after switch to 
HFW diet (5.2 ± 0.2 g/Day) was also significantly higher than Polg mice after switching to 
HFW diet (3.1 ± 0.2 g/Day). The increase in food consumption in both 3 and 7 month old WT 
mice is likely responsible for the increased RER since more calories are entering the body. 
These data show that WT mice develop an acute response in metabolism to HFW diet while 
Polg mice do not respond when changed to HFW diet. In the acute response experiment, 
changes in RER, activity, basal metabolic rate, and energy expenditure (heat) were minimal.  
To determine the long-term effects of diet on these parameters, PolgD257A mice were 
given either NC or HFW diet for 3 months and placed into Oxymax changes to assess global 
metabolism. Wild type mice on both diets did not eat during the experiment and have been 
excluded for the comparison. During the light cycle, RER was similar in Polg-NC and Polg-
HFW mice. During the dark cycle when animals are most active, RER was higher in Polg NC 
mice compared to Polg HFW mice, but the difference was not significant (Fig. 4.14A). Basal 
metabolic rate, activity, and energy expenditure were all similar in Polg NC and Polg HFW 
mice (Fig. 4.14B-D). When combined, the acute response and prolonged response 
experimental data demonstrates that the PolgD257A mutation does not alter the global 
metabolism by increasing the global metabolic rate of the animal on either NC or HFW diet.  
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Figure 4.13: Calorimetry in 3-month-old and 7-month-old PolgD257A mice. Respiratory 
exchange ratio in 3-month-old (A) and 7-month-old (B) wild type and PolgD257A mice given a 
normal diet for 48 hrs followed by high fat diet for 48 hrs. Basal metabolic rate in 3-month-old (C) 
and 7-month-old (F) wild type and PolgD257A mice given a normal diet for 48 hrs followed by high 
fat diet for 48 hrs. Activity in 3-month-old (D) and 7-month-old (G) wild type and PolgD257A mice 
given a normal diet for 48 hrs followed by high fat diet for 48 hrs. Energy expenditure in 3-month-
old (E) and 7-month-old (H) wild type and PolgD257A mice given a normal diet for 48 hrs followed 
by high fat diet for 48 hrs. All data are represented as Mean ± SEM. *** P < 0.001, ** P < 0.01, and 
* P < 0.05 by Tukey-Kramer HSD. 
 
 
 
  141 
 
Figure 4.14: Calorimetry in 7-month-old PolgD257A mice fed either NC or HFW diet for 3 
months. (A) Respiratory exchange ratio in 7-month-old PolgD257A mice given a NC (black) of 
HFW (blue) diet. (B) Basal metabolic rate, (C) Activity, and (D) Energy expenditure 7-month-old 
PolgD257A mice given a NC or HFW diet for 3 months. All data are represented as Mean ± SEM. 
  142 
4.5 Discussion 
Considering the importance of mitochondria in aging, I expected that the PolgD257A 
mutation, which increases mitochondrial DNA mutations, would develop mal-absorption. 
Accumulations of mitochondrial DNA mutations play a role in the development of an 
accelerated aging phenotype (25, 26), and increases in mitochondrial DNA mutations have 
been found in the elderly (10). In addition, mitochondrial DNA mutations have been shown to 
be the underlying genetic factor in several metabolic diseases (43, 44), and have their greatest 
effect in cells that are metabolically active or highly proliferative (17-21). The intestinal 
phenotypes of PolgD257A mice: increased apoptosis and decreased proliferation in the crypt 
and increased enterocyte half-life in the villi, could account for the mal-absorption in aging. In 
this chapter, I tested this hypothesis using mice on NC and on HFW. I found that the 
PolgD257A mice on NC diet were indistinguishable from wild type mice on NC diet. In 
contrast, PolgD257A mice administered HFW diet did not gain weight compared to wild type 
mice administered HFW diet. Insulin sensitivity was impaired in wild type mice but not 
PolgD257A mice on HFW diet. This protection from diet induced obesity and insulin 
resistance was due at least in part because PolgD257A mice on HFW diet had increased 
excretion of fat in the feces. However, fat absorption in PolgD257A mice on HFW diet was 
similar to wild type mice on HFW diet. In the villi, HFW diet increased apoptotic cells to 30%, 
but did not alter apoptosis and proliferation in the crypt compartment in PolgD257A mice. All 
of the metabolic measurements taken during the administration of HFW diet, basal plasma 
glucose, triglycerides, and cholesterol, were significantly lower in mutant mice compared to 
wild type controls suggesting limited dietary absorption in the PolgD257A mice.  
To rule out a digestive problem, pancreatic gene expression of the digestive enzymes 
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revealed that all are produced at normal. These results confirm that enzymes necessary for 
processing the diet as it enters the small intestine are present, although they do not address 
whether the enzymes are active. The digestive enzymes chymotrypsinogen, lipase, co-lipase, 
and amylase all require activation within the small intestine by trypsin, and trypsin requires 
activation from its inactive state, trypsinogen. Enterokinase, also known as enteropeptidase, is 
responsible for converting trypsinogen to trypsin (45). Analysis of enterokinase activity was 
comparable in wild type and PolgD257A mice on HFW diet. These data rule out digestive 
components as a cause for reduced absorption of dietary fats. 
A global increase in metabolism does not account for the differences in fat storage in  
PolgD257A and wild type mice on HFW diet. By measuring global oxygen consumption and 
carbon dioxide respiration, metabolism of various sources of energy were evaluated. 
Respiratory exchange ratio is a calculation based on the amount of CO2 produced/ amount of 
O2 consumed. When RER approaches 1.0, carbohydrates are the primary source of energy. 
When RER approaches 0.7, fat is the primary source of energy. When the PolgD257A mice 
were fed a high fat, high carbohydrate diet, I expected to see an increase utilization of fat and 
an RER approaching 0.7. However, the PolgD257A mice did not alter their pattern of 
utilization of carbohydrates and fats. This is based on the RER not changing dramatically when 
the mice were switched from NC diet to HFW diet. On the other hand, the wild type animals 
responded to the change in diet by consuming primarily carbohydrates. Since the diet is high in 
carbohydrates, this result is not surprising. The reason wild type mice fed HFW diet gain 
significant amounts of weight is likely due to an acute increase in caloric intake (21.47 
kcal/day) compared to PolgD257A (12.7 kcal/day). Furthermore, wild type mice fed HFW diet 
overwhelming use carbohydrates, convert unused carbohydrates to fat for storage, and store 
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excess fat in the adipose tissue while PolgD257A mice fed HFW diet use more fat than 
carbohydrates. In support of this, inguinal and gonadal fat weights were significantly larger in 
WT HFW mice compared to Polg HFW mice. While these results do not show an increase in 
metabolism in PolgD257A mice fed a HFW diet, they do confirm that the PolgD257A 
mutation plays a pivot role in intestinal absorption and adipose storage of fat. 
On a cellular level, I have shown in Chapter 3 that an increase in cell apoptosis and a 
decrease in cell proliferation occurs specifically in the transit amplifying cells located in the 
crypts of Lieberkuhn in the small intestine of PolgD257A mice. In normal small intestines, 
there are low levels of apoptosis observed in the intestinal crypts used primarily as a 
maintenance system to eliminate extra or damaged stem cells within in the intestinal crypt (46, 
47). In aging mice and humans, there is no evidence of increased apoptosis in the crypt region. 
Increased apoptosis has been reported in rats when given a dose of radiation causing apoptosis 
in the proliferating cells of the small intestine (46). Yet the question remained as to whether 
these collective changes are sufficient to cause a functional change in the small intestine. 
Intestinal gene expression did not reveal any specific changes. The evidence presented in 
chapter 3 suggests that villous epithelial cell replacement of the intestinal epithelial cells has 
been reduced. Cell replacement is a common occurrence in the epithelial cells of the small 
intestine with complete cell replenishment estimated to take approximately 3.3 days (48). 
However, cell migration in intestinal epithelial cells of PolgD257A mice is greater than 4 days. 
It is possible that increasing the time for cell renewal of the intestinal epithelial cells would 
allow dysfunctional cells with reduced absorptive capacity to remain for a longer period of 
time. This would explain the defect in absorption as enterocytes are the primary absorptive cell 
in the intestine. Although generally assumed that aging leads to reduced absorptive capacity, 
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whether the retained epithelial cells are dysfunctional enterocytes remains an important 
question, and is currently a hot topic in the gastrointestinal field.  
While the exact mechanism for the reduced lipid absorption in PolgD257A mutants has 
yet to be elucidated, lipid absorption is limited by the PolgD257A mutation prompting a 
concern that administering HFW diet to PolgD257A mice causes malnourishment. However, 
they are absorbing more total fat from diet than NC fed mice, and similar amounts as WT 
HFW mice, and the plasma levels of lipid soluble vitamins D and E were not affected by the 
PolgD257A mutation even under the high dietary lipid load. Although PolgD257A mutation 
caused reduced expression of Glut2 gene in the small intestine and amylase gene in the 
pancreas, monosaccharide carbohydrate absorption (glucose) was not affected in PolgD257A 
mice regardless of diet since administering an oral gavage of glucose produced a normal spike 
in plasma glucose. However, I cannot exclude a possibility that the PolgD257A mutation 
causes a defect in carbohydrate digestion and/or disaccharide conversion to monosaccharide 
since the main source of carbohydrates in the HFW diet is sucrose, which requires conversion 
to glucose before absorption can proceed. It does not appear the PolgD257A mice administered 
HFW diet lack essential nutrients for survival. Overall, the limited caloric intake appears to be 
beneficial to the PolgD257A mice. 
In conclusion, I have demonstrated that the PolgD257A mutation limits lipid absorption 
when a diet high in fat and carbohydrates is administered. However, PolgD257A mice do not 
exhibit any overt signs of intestinal mal-absorption. The most striking evidence for intestinal 
dysfunction in PolgD257A mice is the increase in fecal fat excretion as a consequence of a 
limited fat absorption. This prevents the excess accumulation of body fat and protects from the 
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development of insulin resistance. Establishing a clear mechanism as to why the PolgD257A 
mutation causes the absorption problems remains elusive. 
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C h a p t e r  5  
CONCLUSIONS 
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This dissertation describes the use of animal models to investigate the role of 
mitochondrial DNA mutations in diabetes, obesity, and diabetic complications. While 
mitochondrial DNA mutations are expected to enhance disease especially metabolic disease, 
the results presented here describe the many unexpected findings associated with mitochondrial 
DNA mutations and metabolic diseases in animal models. The significant findings and 
conclusions for each chapter are discussed below. 
Chapter 2 
Significant points 
1. Diabetes improves in diabetic Akita male mice homozygous for the Polg D257A 
mutation. 
2. The improvement in diabetes is due to appetite suppression caused by a premature 
decline in testosterone production associated with increased damage to Leydig cells. 
3. Testosterone replacement in double mutant mice increases hyperglycemia back to levels 
seen in simply diabetic Akita male mice. 
4. Mitochondrial debris is increased in euglycemic double mutant mice and significantly 
increases with testosterone administration suggesting a role of mitochondrial DNA 
mutations in kidney pathology. 
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Discussion and Future directions 
 In this chapter, I describe an unforeseen improvement in Akita diabetic male mice 
homozygous for the PolgD257A mutation. As previously described, the “Akita” mutation has a 
more potent affect on male mice as opposed to female mice (1). In my study, diabetes in the 
double mutant male mice improved to levels that were similar to female Akita mice. A recent 
study illustrated a similar finding when diabetic Akita male mice were gonadectomized 
effectively reducing hyperglycemia (2). The underlining mechanism causing the reduced 
diabetic phenotype in my study was traced to testis dysfunction directly caused by the 
PolgD257A mutation. The dysfunction in the testis causes a change in appetite in the double 
mutant mice that effectively improves diabetes. I also demonstrated that testosterone 
replacement therapy in these double mutant mice returns hyperglycemia back to levels seen in 
simply diabetic mice. While this finding was unexpected, the results of this study uncovered 
the hyperphagic mechanism of diabetes in Akita mice and emphasized the importance of 
hyperphagia in this mouse model of type 1 diabetes. This mechanism is not equivalent to what 
occurs in type 1 diabetes in humans. Type 1 diabetes in humans is characterized by an 
autoimmune response triggering destruction of pancreatic beta cells (3-6). While the 
mechanism described here does not apply to human diabetic patients, it provided convincing 
evidence for the role of testosterone in the hyperglycemia of male mice. 
 Although my initial question of the role of mitochondrial DNA mutations in diabetic 
nephropathy was not answered, this study showed that mitochondrial DNA mutations may be a 
contributing factor to kidney pathology. A previous study has suggested that mitochondrial 
DNA mutations may be involved with enhancing nephropathy (7). It still remains a possibility 
that mitochondrial DNA mutations can affect the kidney, which is a metabolically active organ. 
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However, it is unclear whether the mtDNA mutations act causally with respect to diabetic 
complications, or are just consequences of the condition. 
 Alternative in vivo approaches can be utilized to answer whether mitochondrial DNA 
mutations play a causal role in diabetic nephropathy. The limitation of the current model is that 
global increases in mitochondrial DNA mutations affect multiple organs that contribute to 
improved diabetes. To investigate diabetic nephropathy, a conditional mouse model of 
PolgD257A would prove useful in answering this question. The conditional PolgD257A mouse 
model will be discussed later. Alternatively, kidney transplants could be utilized with 
PolgD257A kidneys as a donor and Akita mice as the recipient. This technique is technically 
challenging even in healthy mice, and would require a larger pool of animals to produce an 
effective experiment. Nevertheless, both of these options could potentially address our 
question. 
Chapter 3 
Significant points 
1. Apoptosis is increased in the intestinal stem and progenitor cells found in the crypts of 
Lieberkuhn. 
2. S-phase cell proliferation is also disrupted in the crypt compartment. 
3. The PolgD257A mutation disrupts the cell cycle of the intestinal stem and progenitor 
cells causing a decrease in cell migration through the small intestine villi.  
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Discussion and Future directions 
 In this chapter, I describe the novel finding that the PolgD257A mutation increases cell 
apoptosis and decreases S-phase cell proliferation. Previously, the PolgD257A mutation was 
described as having increased apoptosis of columnar epithelial cells in the villi of the small 
intestine (8). In my study, the cell cycle is disrupted in these highly proliferative cells of the 
small intestine, and suggests that mitochondrial function plays a central role in the regulation of 
the cell cycle. As previously described in Chapter 3 on page 91, mitochondria are important in 
generating ATP required during the cell cycle and allowing procession through the cell cycle. 
Due to the heterogeneous nature of the PolgD257A crypts, determining an exact mechanism 
proved challenging. It wasn’t until recently that the stem cells of the crypts could be cultured in 
vitro (9). The results of culturing the isolated stem cells reveals a defect in proliferation caused 
by the PolgD257A mutation supporting the in vivo results of the disrupted cell cycle and 
slower cell migration in the small intestine. The intestinal stem cell is adversely affected by the 
PolgD257A mutation that lead to defect in the cell cycle and cell proliferation. Essentially, the 
cells in the crypts of PolgD257A are behaving as though they are experiencing a damage 
response that triggers the higher apoptosis. This event has been described under conditions of 
damage induced by radiation where exposed cells become apoptotic (10). These results, while 
not surprising, underline the importance of the mitochondria in the natural process of cell self-
renewal. This study did not cover the functional aspect of the increase in apoptosis and the 
decrease in cell proliferation. One would assume that mitochondrial dysfunction of the small 
intestine in the PolgD257A mouse would lead to issues with nutrient absorption, however no 
overt phenotype has been described. This prompted the question: Does the increase in 
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apoptosis and decrease in cell proliferation have a functional impact on the small intestine? I 
addressed this question in Chapter 4 of this dissertation. 
 Several reports (including the results described in Chapter 2) demonstrated that the 
PolgD257A mutation affects the testis, hair, skin, small intestine, and bone marrow (8, 11-13). 
The trend here is that all of these affected tissues are highly regenerative organ systems. In fact, 
the PolgD257A mouse is described as a mouse model of premature aging. This may be the case 
in that the PolgD257A mouse exhibits many aspects of human aging. However, the 
PolgD257A mutation seems to cause more problems with basic processes involving cell 
division. It is possible that the PolgD257A mouse model is more representative of a model for 
defects in cell proliferation rather than a model of premature aging. Information relating to the 
basic properties of the human aging small intestine is sparse and not well studied. The 
PolgD257A mutation clearly causes significantly more damage in the stem and progenitor cells 
located in the crypts. Whether this increase in damage is found in aging humans or aging 
rodents remains to be determined.  
 With the results present so far, the PolgD257A mouse could allow for expansion into 
other fields such as cancer. Since it appears that the PolgD257A mouse model has a global 
defect in cell proliferation, it would be interesting to cross this mouse with well-established 
models of cancer. Such a strategy would allow us to determine the contribution of 
mitochondrial dysfunction to cancer considering cancer is based on a disruption of the cell 
cycle leading to uncontrolled cell growth. Other groups may be pursuing this idea, but the 
results have yet to be reported.  
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Chapter 4 
Significant points 
1. The PolgD257A mutation does not affect nutrient absorption in mice maintained on NC 
diet. 
2. The PolgD257A mutation protects against diet induced obesity and insulin resistance. 
3. The increases in apoptosis and decreases in cell proliferation in the small intestine are 
likely triggering the mal-absorption of lipids when mice are administered HFW diet. 
4. The failure to gain weight on the HFW diet is not the result of increased metabolism or 
increased energy expenditure. 
 Discussion and Future directions 
 Aging is thought to be the main contributing factor leading to the apparent mal-
absorption yet the exact mechanism behind the dysfunction of the aging small intestine is not 
known. The goal of the experiments described in this chapter is to elucidate the effect of 
increasing mtDNA mutations in the small intestine on nutritional absorption, and on obesity 
and type 2 diabetes. I used the prematurely aging PolgD257A mutant mouse as a genetic tool 
to answer this question, and determine the role of mitochondrial DNA mutations in the 
functionality of the small intestine. In this chapter, I demonstrate that the PolgD257A mutation 
can prevent HFW diet induced obesity. I was not surprised to find that the PolgD257A mutant 
mice on NC diet are not affected by the changes in cell cycle and apoptosis in the small 
intestine since the mice used in both Chapters 2 and 3 were fed a NC diet and no overt 
phenotype was present. However, PolgD257A mice on HFW diet were protected against diet-
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induced obesity and insulin resistance. Both digestion and metabolism did not change in the 
presence of the PolgD257A mutation suggesting another mechanism. It is likely that the 
changes in apoptosis and cell cycle in the small intestine of the PolgD257A mice impairs their 
ability to absorb dietary lipids preventing the accumulation of fat without disturbing nutritional 
balance. The results of the acid steatocrit determined that fat is not being absorbed efficiently in 
the PolgD257A mice, and this result may be the only evidence for the failure of PolgD257A 
mice to accumulate fat.  
 Alternatively, one possible mechanism for the reduced obesity phenotype of 
PolgD257A mice on HFW diet could be the reduced ability to breakdown carbohydrates. It is 
likely that both carbohydrates and lipids are required for fat storage and obesity. A high dietary 
intake of carbohydrates along with high consumption of lipids could work in unison. In this 
situation, both excess carbohydrates and lipids would be stored together in the fat depots 
allowing a rapid accumulation of fat. If PolgD257A mice cannot process carbohydrates as 
efficiently during digestion as wild type mice then the PolgD257A mice would not develop the 
obesity phenotype. This could easily explain the rapid accumulation of fat in wild type mice in 
the acute experiments and the inability of PolgD257A mice to store any fat during the 
experiment. One finding during this study was that PolgD257A mice produce less pancreatic 
amylase. Amylase is essential for the breakdown of carbohydrates during the initial stages of 
digestion (14). While amylase was low in PolgD257A mice regardless of diet, it is not the only 
enzyme responsible for the breakdown of carbohydrates. The HFW diet contains sucrose as its 
main source of carbohydrates. Sucrose is broken down into glucose and fructose by the enzyme 
sucrase (15). In obese mice, sucrase increases with age and signifies the start of obesity (16). 
For instance, if sucrase activity is low in the PolgD257A mice, this would lead to a reduction in 
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the break down of complex disaccharides to the easily absorbed monosaccharides. 
Carbohydrate metabolism has been linked to a decrease sucrase leading to mal-absorption by 
the small intestine (17). Monosaccharides such as glucose can be absorbed by active transport 
(Sglt), passive transport (Glut2), or by alternative diffusion pathways in the small intestine (15). 
Whether this mechanism is plausible remains to be determined, and should be a focus for 
further study. 
Creation of a Conditional Mouse Model of PolgD257A 
The use of a conditional mouse models has its advantages over typical knock in or 
knock out mouse models. In the case of mitochondrial DNA polymerase gamma, deletion of 
the gene proves to be embryonic lethal (18). Engineering a mutation into Polg (D257A) leads 
to a global expression of the mutant allele (8, 12). In order to ask more intricate questions 
involving mitochondrial DNA mutations and diabetic related complications, I set out to create 
a conditional knock-in of the PolgD257A mutation. This model will allow the tissue specific 
expression of PolgD257A, and bypass the complications associated with global expression of 
PolgD257A as I have described in Chapter 2, 3, and 4. The targeting vector was successfully 
engineered, and introduced into multiple embryonic stem (ES) cell lines. Multiple positive ES 
clones were created and microinjected into blastocysts. The chimeras generated were of 
exceptional quality. Chimeras were bred to wild type mice to generate a germ line transmitted 
mouse with the targeting of the conditional PolgD257A mutation. However, multiple attempts 
to generate a germ line animal failed.  
Based on my previous work with the PolgD257A mouse model, it has become apparent 
that a conditional allele of PolgD257A would provide an exceptional tool to determine the 
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effect of accumulating mitochondrial DNA mutations in individual tissues while maintaining 
diabetes. As I have shown in Chapter 2, the PolgD257A mutation causes a disruption of the 
testis that ultimately affects appetite in the diabetic mice leading to an improvement in 
hyperglycemia. Due to this improvement in diabetes, diabetic induced complications did not 
develop. In this case, a conditional allele could bypass the testis dysfunction and target the 
kidney allowing us to evaluate the role of accumulating mitochondrial DNA mutations in 
nephropathy. In Chapters 3 and 4, intestinal related problems were observed in PolgD257A 
mice leading to mal-absorption on HFW diet. The intestinal changes and subsequent mal 
absorption would have a detrimental effect on any metabolic studies in the PolgD257A mouse. 
In this case, a conditional allele could bypass the small intestine dysfunction and target 
individual tissue for long term studies on the effects of accumulating mitochondrial DNA 
mutations (aging) on individual organs. 
 The PolgD257A conditional targeting vector was created as follows: 1) the cDNA 
(exons 3-26) for Polg was fused to the endogenous exon 3 in the genome sequence of Polg; 2) 
the mutated exon 3 with the D257A mutation was created by PCR and sequenced for accuracy; 
and 3) the cDNA from exon 3 to exon 26 was flanked by LoxP sites to allow Cre mediated 
deletion. Figure 5.1 illustrates the genomic structure of Polg (Fig. 5.1A), the conditional 
targeting vector (Fig. 5.1B), and the targeted allele after homologous recombination (Fig. 
5.1C). Once germ line transmission of the conditional allele was achieved, the mutant mouse 
would express wild type Polg until exposure of the Cre recombinase (Fig. 5.2A). In the 
presence of Cre recombinase, the wild type Polg sequence is excised and the PolgD257A 
mutant is expressed (Fig. 5.2B). The completed targeting vector was electroporated into B6 
(C57BL/6) embryonic stem cells. PCR screening of the targeted B6 ES clones yielded 4 
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positives out of 194 clones screened. Southern blot analysis of the PCR positive clones 
confirmed that 3 out of 4 ES clones were correctly targeted for the conditional PolgD257A 
allele (Fig. 5.3A). All 3 clones were used for microinjection yielding 46 potential chimeras. 
Using B6 cells requires PCR screening of all mice to determine chimeras since coat color 
cannot be used in this approach. Eleven male chimeras and two female chimeras were 
confirmed by PCR. All 13 chimeras were bred to wild type C57BL/6 mice. Offspring of 
chimeras crossed to wild type mice were screened for both Neomycin and the PolgD257A 
mutation. Breeding of these animals proceeded for 18 months with no positive germ line 
transmission. 
A second targeting experiment was performed using E14 (Ola/129) embryonic stem 
cells. This approach would allow for determination of chimeras by coat color, which is the 
standard approach for generating gene targeted mice. PCR screening of the targeted E14 ES 
clones yielded 20 positives out of 242 clones screened. Southern blot analysis of the PCR 
positive clones confirmed that 18 out of 20 ES clones were correctly targeted for the 
conditional PolgD257A allele (Fig. 5.3B). Six individual clones (1F3, 1F10, 3A3, 3D10, 3F1, 
and 3H3) were microinjected. However, no chimeras were produced. The remaining clones 
were pooled and microinjected over a 5-day period. Over 20 excellent chimeras (based on cost 
color >70% agouti) were generated by microinjection of these pooled ES clones. All chimeras 
were bred to wild type C57BL/6 mice. Offspring of this breeding between chimeras and wild 
type mice produced either black or agouti pups with agouti pups indicating a transmission 
event. One chimera consistently produced both black and agouti litters. However, screening of 
the agouti pups revealed no positive germ line transmission of conditional PolgD257A 
mutation. Breeding of these animals proceeded for >12 months with no positive germ line 
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transmission. The breeding of these chimeras continued for 16 months at which point the 
chimeras were no longer producing pups. Thus, I discontinued the generation of this mouse 
model. 
  In conclusion, this targeting plan produced no viable germ line animals, while this 
approach was discontinued. The targeting vector was sequenced for errors introduced during 
PCR and cloning, and no errors were found through out the targeting vector. PCR on the 
positive ES clones showed that every component engineered into the targeting vector was 
found robustly in the positive ES clones. The PolgD257A mutation introduces a new restriction 
site, XhoI, in exon 3. I confirmed by PCR and digest with XhoI that the PolgD257A mutation 
was present in the ES clones. It is unclear why germ line transmission was not achieved for this 
experiment. It could be possible that the cDNA or other components such as the selection 
markers still being present creates a toxicity that prevents germ line transmission. Other 
targeting approaches such as the unidirectional Cre-LoxP system (19) could be utilized in order 
to generate this conditional allele.  
Overall Conclusion 
The goal of this dissertation was to explore the role of mitochondrial DNA mutations in 
the development of diabetes, obesity, and diabetic complications. The reversal of diabetes was 
surprising since mitochondrial dysfunction is widely accepted to cause metabolic disorders. 
Nevertheless, the first study determined the role of testosterone in the reduction of appetite and 
improvement in diabetes underlying the importance of hyperphagia in the Akita type 1 diabetic 
model. This study also provided further support for the reason behind the severity of diabetes 
in Akita males versus the mild diabetes found in Akita females. While diabetic complications 
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could not be assessed using the PolgD257A mice, the mitochondrial debris seen in double 
mutant mice provides a glimpse into the role of mitochondrial DNA mutations play in the 
development of kidney pathology. The second study shows the importance of functional 
mitochondria in the maintenance of intestinal stem and progenitors cells. The PolgD257A 
mutation causes increased apoptosis and decreased cell proliferation in the stem and progenitor 
cells in the crypts of Lieberkuhn that has not been reported in these mice as well as in aging 
humans and rodents. I demonstrated that mitochondrial dysfunction is pivotal in disrupting the 
cell cycle and reducing intestinal epithelial cell migration. The final study explored the 
functional aspects of these changes in the small intestine when placed under the dietary stress 
of HFW diet. HFW diet causes obesity in wild type mice, but not in PolgD257A mice. This 
protective effect is likely the result of the increase in apoptosis and the decrease in cell 
proliferation that causes the lipid mal-absorption. 
These studies have provided insight into the role of mitochondrial DNA mutations in 
the regulation of diabetes in Akita male mice, the regulation of cell cycle in intestinal stem and 
progenitor cells, and the regulation of small intestine function during high dietary lipid loads. 
These unexpected results have provided a precautionary light on the use of PolgD257A mice in 
metabolic studies and the importance of a PolgD257A conditional mouse model in any further 
metabolic study.  
  165 
 
 
 
Figure 5.1: Illustration of Polg genomic sequence and targeting of conditional 
targeting vector by homologous recombination. (A) Genomic structure of Polg 
consisting of 26 exons. Green D represents the wild type exon 3 with Aspartic Acid in 
amino acid position 257. (B) Structure of the PolgD257A conditional targeting vector. Blue 
A represents the mutant exon 3 with Alanine in amino acid position 257. Diphtheria toxin 
was used as a marker for negative selection of non-homologous recombination. Neomycin  
(Neo) was used for positive selection of homologous recombination. Thymidine kinase 
(TK) was used as a negative selection for non-Flp mediated recombination. (C) Targeted 
Polg allele with wild type PolgD257 surrounded by LoxP sites followed by the PolgD257A 
mutation. Not I to Nsi I was used for genomic screening to differentiate wild type (10.4 Kb) 
and the targeted allele (13.6 Kb). 
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Figure 5.2: Illustration of Cre-mediated excision of the PolgD257 resulting in 
PolgD257A. (A) Targeted Polg conditional allele prior to Cre recombinase. (B) Mutant 
PolgD257A allele after Cre recombinase deletion of PolgD257. 
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Figure 5.3: Southern blots of conditional PolgD257A targeting. (A) Targeting in B6 ES 
cells yielded 3 of 4 positively target ES clones. (B) Targeting in E14 ES cells yielded 18 of 
20 positively targeted ES clones. Black arrows represents the size of the wild type 
PolgD257 allele while blue arrows represents the size of the PolgD257A conditional allele. 
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